EeMei personal page - To The Moon

EeMei

EeMei

No personal profile

15Follow

1Followers

0Topic

0Badge

2021-06-30

??

In the first half of the year, these 11 biopharmaceutical companies invested by Hillhouse have officially IPO

2021-06-30

??

Opening: Nasdaq and S&P hit another record high, blockchain sector rose broadly

2021-06-30

??

Sorry, the original content has been removed

2021-06-30

???

Sorry, the original content has been removed

2021-06-30

???

Ding Dong Maicai officially landed on NYSE and opened 21% on the first day

2021-06-28

???

Premarket: Surge 54%! Goldman Sachs "Crazy Singing More" a gene compilation company

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4087745047715700","uuid":"4087745047715700","gmtCreate":1624641986890,"gmtModify":1624711532420,"name":"EeMei","pinyin":"eemei","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":15,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":153914555,"gmtCreate":1625004492477,"gmtModify":1703849749154,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087745047715700","idStr":"4087745047715700"},"themes":[],"title":"","htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153914555","repostId":"1102942162","repostType":4,"repost":{"id":"1102942162","kind":"news","pubTimestamp":1624972114,"share":"https://ttm.financial/m/news/1102942162?lang=en_US&edition=fundamental","pubTime":"2021-06-29 21:08","market":"us","language":"zh","title":"In the first half of the year, these 11 biopharmaceutical companies invested by Hillhouse have officially IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1102942162","media":"医药观澜","summary":"2021年高瓴的IPO方向以新一代基因治疗、细胞疗法的创新药为主。就其投资的企业类型来看，创新研发能力强、处于早期阶段的科创企业更受青睐。\n公开资料显示，2021年以来，已经有11家高瓴投资的生物医药","content":"<p>In 2021, Hillhouse's IPO direction will focus on innovative drugs for new generation gene therapy and cell therapy. As far as the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and in the early stage are more favored.</p><p>Public information shows that since 2021, 11 biomedical companies invested by Hillhouse have officially IPO on different stock exchanges. Throughout the 11 IPO projects, they are all technological innovation-driven companies. Among them, there are 7 cutting-edge companies focusing on innovative therapies. Their research fields include cell therapy, innovative ophthalmic drugs, autoimmune diseases and so on. This article will share basic information about these 7 companies for readers' information only.</p><p>1. Keji Pharmaceutical</p><p>Research area: Cell therapy</p><p>Keji Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative cell therapies for the treatment of solid tumors and hematological malignancies. Since its establishment, Keji Pharmaceutical has been developing innovative and differentiated innovative products focusing on CAR-T cell therapy. Public information shows that the company's CAR-T product candidates are evidence-based on new tumor-related antigens and have been carefully designed and optimized to reduce common side effects of existing CAR-T therapies. In June 2021, Keji Pharmaceutical was officially listed on the Hong Kong Stock Exchange.<img src=\"https://static.tigerbbs.com/0718a4dbb06171c8ac471c5b084ded19\" tg-width=\"345\" tg-height=\"129\" referrerpolicy=\"no-referrer\">It is reported that Keji Pharmaceutical has now established a pipeline under development containing 11 product candidates, and 6 are in the clinical development stage. Among them, BCMA-targeted CAR-T therapy CT053 has been granted advanced therapy designation for regenerative medicine (RMAT) and orphan drug designation by the FDA, priority drug designation (PRIME) and orphan drug designation granted by the European Medicines Agency (EMA), and China Breakthrough therapeutic varieties granted by the National Food and Drug Administration (NMPA). In addition, the company's products under development also include CLDN18.2 targeting CAR-T products, autologous CAR-T candidates targeting phosphatidylinositol proteoglycan-3 (GPC3), and so on.</p><p>2. Century Therapeutics</p><p>Research area: Cell therapy</p><p>Century Therapeutics is committed to harnessing the potential of adult stem cells to develop cell therapy products for the treatment of cancer to overcome the limitations of first-generation cell therapies. The company's technology platform relies on induced pluripotent stem cells (iPSCs) with unlimited self-renewal capabilities. The technology uses multiple rounds of cell engineering to create a master cell bank that can expand and differentiate into immune effector cells, thereby providing a large number of allogeneic, homologous therapeutic products. In June 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/ebdab209c719a1865a19e7329210a703\" tg-width=\"570\" tg-height=\"190\" referrerpolicy=\"no-referrer\">According to reports, Century Therapeutics' preclinical R&D projects include a variety of induced pluripotent stem cell-derived CAR-iT and CAR-iNK cell products, which are intended to be developed for the treatment of hematological cancers and solid tumors. Among them, the drug candidate CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy, which is intended to be developed for the treatment of relapsed/refractory B-cell lymphoma. The drug candidate CNTY-103 is a CAR-iNK candidate targeting CD133/EGFR and is intended for the treatment of recurrent glioblastoma (GBM). In addition, the company is also developing drug candidates for the treatment of relapsed/refractory B-cell lymphoma, acute myeloid leukemia (AML) and other diseases.</p><p>3. Lyell Immunopharma</p><p>Research area: Cell therapy</p><p>Lyell Immunopharma aims to develop solid tumor T cell therapies with \"curative\" potential by \"reprogramming\" T cells. In June 2021, the company officially landed on the Nasdaq. Lyell believes that T cell therapy mainly faces two major obstacles in the treatment of solid tumors: First, the depletion of T cells causes it to lose its function of killing tumor cells; Second, the stem cell characteristics of T cells are not durable enough, resulting in limited continuous proliferation and renewal ability of T cell therapy. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms Gen-R and Epi-R to address these barriers to develop innovative therapies.<img src=\"https://static.tigerbbs.com/156517955166f0a82d8bd8c0e03602f3\" tg-width=\"200\" tg-height=\"200\" referrerpolicy=\"no-referrer\">According to reports, LYL797 developed by Lyell is a CAR-T therapy under development targeting ROR1 antigen. This product adds a safety switch based on optimized epidermal growth factor receptor (EGFR) and is intended to be developed for the treatment of ROR1 expression. Non-small cell lung cancer, triple negative breast cancer and other cancers. Another product candidate, LYL845, is an autologous tumor infiltrating lymphocyte (TIL) therapy that is expected to treat a variety of solid tumors. In addition, the company is also working with GlaxoSmithKline (GSK) to develop TCR-T cell therapies targeting NY-ESO-1.</p><p>4. Talaris Therapeutics</p><p>Research area: Cell therapy</p><p>Talaris Therapeutics is committed to developing treatments through disposable cell therapy to permanently solve the problem of organ transplant patients needing long-term immunosuppressive therapy. In May 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/94382e61a569a56d90efdf9e700b4aa4\" tg-width=\"640\" tg-height=\"334\" referrerpolicy=\"no-referrer\">The side effects of long-term immunosuppressive drugs have made Dr. Suzanne Ildstad, the founder of Talaris, determined to develop an innovative treatment to improve the body's immune tolerance. Her research found that there are facilitating cells in the bone marrow. Unlike stem cells, these cells can help stem cells transplanted into the host migrate into the bone marrow, where immune cells and other blood cells are generated. In addition, promoting cells can also enhance the host's immune tolerance and reduce the risk of graft-versus-host disease (GVHD). According to reports, FCR001, a cell therapy under development developed by Talaris, has entered the late-stage clinical trial stage, and it is planned to be developed and treated for patients who have previously received living donor kidney transplantation and patients with severe autoimmune diseases. Previously, the FDA has granted FCR001 orphan drug designation and advanced therapy designation for regenerative medicine (RMAT).</p><p>5. Zhaoke Ophthalmology</p><p>Research area: Ophthalmology innovative drugs</p><p>Zhaoke Ophthalmology is committed to the discovery, development and commercialization of ophthalmic therapies. Through self-development or licensed introduction, Zhaoke Ophthalmology has established a comprehensive ophthalmic drug pipeline comprising 25 drug candidates, including 13 innovative drugs and 12 generic drugs, covering most major ophthalmic indications affecting the anterior and posterior segments of the eye. In April 2021, Zhaoke Ophthalmology was officially listed on the Hong Kong Stock Exchange.</p><p><img src=\"https://static.tigerbbs.com/d46d549a89fd16eba51aeeef02ba7eab\" tg-width=\"640\" tg-height=\"177\" referrerpolicy=\"no-referrer\"></p><p>It is reported that Zhaoke Ophthalmology's preliminary research and development focus focuses on five major ophthalmological indications in China, namely dry eye syndrome (DED), wet senile macular disease (wAMD), diabetic macular edema (DME), myopia and glaucoma. Many ophthalmic diseases develop in multiple stages due to the presence of multiple pathological processes. Therefore, most ophthalmic diseases are heterogeneous diseases. For different ophthalmic indications, Zhaoke Ophthalmology's development strategy is to choose to develop multiple drug candidates with different mechanisms of action, hoping to bring flexible treatment options to patients through monotherapy or combination administration.</p><p>6. Design Therapeutics</p><p>Research Area: Autoimmune Diseases</p><p>Design Therapeutics, which is committed to developing drugs to treat severe degenerative diseases caused by nucleotide repeat amplification, went public on the Nasdaq in March 2021. Nucleotide repeat disease is a kind of genetic disease caused by the repeated amplification of certain short sequences of genes. Depending on their location, repeated sequences may lead to alterations in the regulation of gene expression or to the production of toxic gene products, which are considered to be important factors contributing to degenerative diseases.</p><p><img src=\"https://static.tigerbbs.com/bea91a3c2d92095a7a6f6b3a4d4c8a53\" tg-width=\"640\" tg-height=\"187\" referrerpolicy=\"no-referrer\">According to the official website of Design Therapeutics, the company currently has two major research projects. One of the research projects targeted patients with Friedreich's ataxia (FA). FA is one of the most common types of inherited ataxia. Due to mutations in the FXN gene, the production of frataxin is restricted, which in turn leads to various debilitating symptoms and complications. Another research project targeted the indication of myotonic dystrophy type-1 (DM1). DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease caused by a mutation in the DMPK gene that affects skeletal muscle, heart, brain, and other organs. The main features of the disease include muscle weakness, myotonia (slow muscle relaxation), and early cataracts. Furthermore, affected individuals often experience arrhythmias and changes in neuropsychological functioning.</p><p>7. Instil Bio</p><p>Research area: Cell therapy</p><p>Instil Bio, a global clinical-stage cell therapy company dedicated to the development of tumor-infiltrating lymphocyte therapies for the treatment of cancer, was listed on Nasdaq in March 2021. According to the information from Instil Bio's official website, the company's fastest-developed product under development is ITIL-168, and its clinical trial for the treatment of advanced melanoma is in the phase 1 clinical trial stage. In addition, ITIL-168 is also intended to be developed for the treatment of cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC) and cervical cancer.<img src=\"https://static.tigerbbs.com/10d035fb5dbb022afd385010f2bad15c\" tg-width=\"575\" tg-height=\"269\" referrerpolicy=\"no-referrer\">In addition to the above-mentioned companies, Hillhouse invested in Nanotechnology (research field: nanospheres), Times Angel (research field: oral instruments), Xintong Medical (research field: heart valves), and Beikang Medical (research field: in vitro diagnosis) has also been IPO this year. Due to space limitations, this article will not introduce them one by one.</p><p>For now, Hillhouse's IPO direction in 2021 is dominated by innovative drugs for new generation gene therapy and cell therapy. As far as the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and in the early stage are more favored. For most of these projects, Hillhouse has made multiple rounds of investment and is a long-term backer of these companies.</p><p>It is expected that with the help of capital, these enterprises can introduce innovative products to the market as soon as possible to benefit human health.</p>","source":"lsy1593326364857","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>In the first half of the year, these 11 biopharmaceutical companies invested by Hillhouse have officially IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIn the first half of the year, these 11 biopharmaceutical companies invested by Hillhouse have officially IPO\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">医药观澜</strong><span class=\"h-time small\">2021-06-29 21:08</span>\n</p>\n</h4>\n</header>\n<article>\n<p>In 2021, Hillhouse's IPO direction will focus on innovative drugs for new generation gene therapy and cell therapy. As far as the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and in the early stage are more favored.</p><p>Public information shows that since 2021, 11 biomedical companies invested by Hillhouse have officially IPO on different stock exchanges. Throughout the 11 IPO projects, they are all technological innovation-driven companies. Among them, there are 7 cutting-edge companies focusing on innovative therapies. Their research fields include cell therapy, innovative ophthalmic drugs, autoimmune diseases and so on. This article will share basic information about these 7 companies for readers' information only.</p><p>1. Keji Pharmaceutical</p><p>Research area: Cell therapy</p><p>Keji Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative cell therapies for the treatment of solid tumors and hematological malignancies. Since its establishment, Keji Pharmaceutical has been developing innovative and differentiated innovative products focusing on CAR-T cell therapy. Public information shows that the company's CAR-T product candidates are evidence-based on new tumor-related antigens and have been carefully designed and optimized to reduce common side effects of existing CAR-T therapies. In June 2021, Keji Pharmaceutical was officially listed on the Hong Kong Stock Exchange.<img src=\"https://static.tigerbbs.com/0718a4dbb06171c8ac471c5b084ded19\" tg-width=\"345\" tg-height=\"129\" referrerpolicy=\"no-referrer\">It is reported that Keji Pharmaceutical has now established a pipeline under development containing 11 product candidates, and 6 are in the clinical development stage. Among them, BCMA-targeted CAR-T therapy CT053 has been granted advanced therapy designation for regenerative medicine (RMAT) and orphan drug designation by the FDA, priority drug designation (PRIME) and orphan drug designation granted by the European Medicines Agency (EMA), and China Breakthrough therapeutic varieties granted by the National Food and Drug Administration (NMPA). In addition, the company's products under development also include CLDN18.2 targeting CAR-T products, autologous CAR-T candidates targeting phosphatidylinositol proteoglycan-3 (GPC3), and so on.</p><p>2. Century Therapeutics</p><p>Research area: Cell therapy</p><p>Century Therapeutics is committed to harnessing the potential of adult stem cells to develop cell therapy products for the treatment of cancer to overcome the limitations of first-generation cell therapies. The company's technology platform relies on induced pluripotent stem cells (iPSCs) with unlimited self-renewal capabilities. The technology uses multiple rounds of cell engineering to create a master cell bank that can expand and differentiate into immune effector cells, thereby providing a large number of allogeneic, homologous therapeutic products. In June 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/ebdab209c719a1865a19e7329210a703\" tg-width=\"570\" tg-height=\"190\" referrerpolicy=\"no-referrer\">According to reports, Century Therapeutics' preclinical R&D projects include a variety of induced pluripotent stem cell-derived CAR-iT and CAR-iNK cell products, which are intended to be developed for the treatment of hematological cancers and solid tumors. Among them, the drug candidate CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy, which is intended to be developed for the treatment of relapsed/refractory B-cell lymphoma. The drug candidate CNTY-103 is a CAR-iNK candidate targeting CD133/EGFR and is intended for the treatment of recurrent glioblastoma (GBM). In addition, the company is also developing drug candidates for the treatment of relapsed/refractory B-cell lymphoma, acute myeloid leukemia (AML) and other diseases.</p><p>3. Lyell Immunopharma</p><p>Research area: Cell therapy</p><p>Lyell Immunopharma aims to develop solid tumor T cell therapies with \"curative\" potential by \"reprogramming\" T cells. In June 2021, the company officially landed on the Nasdaq. Lyell believes that T cell therapy mainly faces two major obstacles in the treatment of solid tumors: First, the depletion of T cells causes it to lose its function of killing tumor cells; Second, the stem cell characteristics of T cells are not durable enough, resulting in limited continuous proliferation and renewal ability of T cell therapy. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms Gen-R and Epi-R to address these barriers to develop innovative therapies.<img src=\"https://static.tigerbbs.com/156517955166f0a82d8bd8c0e03602f3\" tg-width=\"200\" tg-height=\"200\" referrerpolicy=\"no-referrer\">According to reports, LYL797 developed by Lyell is a CAR-T therapy under development targeting ROR1 antigen. This product adds a safety switch based on optimized epidermal growth factor receptor (EGFR) and is intended to be developed for the treatment of ROR1 expression. Non-small cell lung cancer, triple negative breast cancer and other cancers. Another product candidate, LYL845, is an autologous tumor infiltrating lymphocyte (TIL) therapy that is expected to treat a variety of solid tumors. In addition, the company is also working with GlaxoSmithKline (GSK) to develop TCR-T cell therapies targeting NY-ESO-1.</p><p>4. Talaris Therapeutics</p><p>Research area: Cell therapy</p><p>Talaris Therapeutics is committed to developing treatments through disposable cell therapy to permanently solve the problem of organ transplant patients needing long-term immunosuppressive therapy. In May 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/94382e61a569a56d90efdf9e700b4aa4\" tg-width=\"640\" tg-height=\"334\" referrerpolicy=\"no-referrer\">The side effects of long-term immunosuppressive drugs have made Dr. Suzanne Ildstad, the founder of Talaris, determined to develop an innovative treatment to improve the body's immune tolerance. Her research found that there are facilitating cells in the bone marrow. Unlike stem cells, these cells can help stem cells transplanted into the host migrate into the bone marrow, where immune cells and other blood cells are generated. In addition, promoting cells can also enhance the host's immune tolerance and reduce the risk of graft-versus-host disease (GVHD). According to reports, FCR001, a cell therapy under development developed by Talaris, has entered the late-stage clinical trial stage, and it is planned to be developed and treated for patients who have previously received living donor kidney transplantation and patients with severe autoimmune diseases. Previously, the FDA has granted FCR001 orphan drug designation and advanced therapy designation for regenerative medicine (RMAT).</p><p>5. Zhaoke Ophthalmology</p><p>Research area: Ophthalmology innovative drugs</p><p>Zhaoke Ophthalmology is committed to the discovery, development and commercialization of ophthalmic therapies. Through self-development or licensed introduction, Zhaoke Ophthalmology has established a comprehensive ophthalmic drug pipeline comprising 25 drug candidates, including 13 innovative drugs and 12 generic drugs, covering most major ophthalmic indications affecting the anterior and posterior segments of the eye. In April 2021, Zhaoke Ophthalmology was officially listed on the Hong Kong Stock Exchange.</p><p><img src=\"https://static.tigerbbs.com/d46d549a89fd16eba51aeeef02ba7eab\" tg-width=\"640\" tg-height=\"177\" referrerpolicy=\"no-referrer\"></p><p>It is reported that Zhaoke Ophthalmology's preliminary research and development focus focuses on five major ophthalmological indications in China, namely dry eye syndrome (DED), wet senile macular disease (wAMD), diabetic macular edema (DME), myopia and glaucoma. Many ophthalmic diseases develop in multiple stages due to the presence of multiple pathological processes. Therefore, most ophthalmic diseases are heterogeneous diseases. For different ophthalmic indications, Zhaoke Ophthalmology's development strategy is to choose to develop multiple drug candidates with different mechanisms of action, hoping to bring flexible treatment options to patients through monotherapy or combination administration.</p><p>6. Design Therapeutics</p><p>Research Area: Autoimmune Diseases</p><p>Design Therapeutics, which is committed to developing drugs to treat severe degenerative diseases caused by nucleotide repeat amplification, went public on the Nasdaq in March 2021. Nucleotide repeat disease is a kind of genetic disease caused by the repeated amplification of certain short sequences of genes. Depending on their location, repeated sequences may lead to alterations in the regulation of gene expression or to the production of toxic gene products, which are considered to be important factors contributing to degenerative diseases.</p><p><img src=\"https://static.tigerbbs.com/bea91a3c2d92095a7a6f6b3a4d4c8a53\" tg-width=\"640\" tg-height=\"187\" referrerpolicy=\"no-referrer\">According to the official website of Design Therapeutics, the company currently has two major research projects. One of the research projects targeted patients with Friedreich's ataxia (FA). FA is one of the most common types of inherited ataxia. Due to mutations in the FXN gene, the production of frataxin is restricted, which in turn leads to various debilitating symptoms and complications. Another research project targeted the indication of myotonic dystrophy type-1 (DM1). DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease caused by a mutation in the DMPK gene that affects skeletal muscle, heart, brain, and other organs. The main features of the disease include muscle weakness, myotonia (slow muscle relaxation), and early cataracts. Furthermore, affected individuals often experience arrhythmias and changes in neuropsychological functioning.</p><p>7. Instil Bio</p><p>Research area: Cell therapy</p><p>Instil Bio, a global clinical-stage cell therapy company dedicated to the development of tumor-infiltrating lymphocyte therapies for the treatment of cancer, was listed on Nasdaq in March 2021. According to the information from Instil Bio's official website, the company's fastest-developed product under development is ITIL-168, and its clinical trial for the treatment of advanced melanoma is in the phase 1 clinical trial stage. In addition, ITIL-168 is also intended to be developed for the treatment of cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC) and cervical cancer.<img src=\"https://static.tigerbbs.com/10d035fb5dbb022afd385010f2bad15c\" tg-width=\"575\" tg-height=\"269\" referrerpolicy=\"no-referrer\">In addition to the above-mentioned companies, Hillhouse invested in Nanotechnology (research field: nanospheres), Times Angel (research field: oral instruments), Xintong Medical (research field: heart valves), and Beikang Medical (research field: in vitro diagnosis) has also been IPO this year. Due to space limitations, this article will not introduce them one by one.</p><p>For now, Hillhouse's IPO direction in 2021 is dominated by innovative drugs for new generation gene therapy and cell therapy. As far as the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and in the early stage are more favored. For most of these projects, Hillhouse has made multiple rounds of investment and is a long-term backer of these companies.</p><p>It is expected that with the help of capital, these enterprises can introduce innovative products to the market as soon as possible to benefit human health.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://wallstreetcn.com/articles/3634131\">医药观澜</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/890dd2dfb205aa8aa1d140672304b3c8","relate_stocks":{"IPSC":"Century Therapeutics, Inc.","02171":"科济药业-B"},"source_url":"https://wallstreetcn.com/articles/3634131","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102942162","content_text":"2021年高瓴的IPO方向以新一代基因治疗、细胞疗法的创新药为主。就其投资的企业类型来看，创新研发能力强、处于早期阶段的科创企业更受青睐。\n公开资料显示，2021年以来，已经有11家高瓴投资的生物医药企业，在不同的证券交易所正式IPO。纵观11个IPO项目，均为科技创新驱动型公司。其中，有7家专注创新疗法的新锐公司，他们的研究领域包括细胞治疗、眼科创新药物、自身免疫疾病等等。本文将分享这7家公司的基本信息，仅供读者参阅。\n1、科济药业\n研究领域：细胞治疗\n科济药业是一家临床阶段的生物医药公司，专注于治疗实体瘤和血液恶性肿瘤的创新细胞疗法。自成立以来，科济药业一直在研发以CAR-T细胞疗法为重点的创新及差异化创新产品。公开资料显示，该公司CAR-T候选产品循证新型肿瘤相关抗原，并经过精心设计和优化，以减少现有CAR-T疗法常见的副作用。2021年6月，科济药业正式在港交所挂牌。据悉，科济药业现已建立一条包含11款候选产品的在研管线，且6款正处于临床开发阶段。其中，BCMA靶向CAR-T疗法CT053曾获FDA授予的再生医学先进疗法认定（RMAT）和孤儿药资格，欧洲药品管理局（EMA）授予的优先药物资格（PRIME）和孤儿药资格，以及中国国家药监局（NMPA）授予的突破性治疗品种。此外，该公司的在研产品还包括CLDN18.2靶向CAR-T产品、靶向磷脂酰肌醇蛋白聚糖-3（GPC3）的自体CAR-T候选产品等等。\n2、Century Therapeutics\n研究领域：细胞治疗\nCentury Therapeutics致力于利用成体干细胞的潜力，开发治疗癌症的细胞疗法产品，以克服第一代细胞疗法的局限性。该公司的技术平台依托于具有无限自我更新能力的诱导多能干细胞（iPSC）。该技术通过多轮细胞工程来创建主细胞库，这些细胞可扩展和分化成免疫效应细胞，从而提供大量同种异体、同源的治疗产品。2021年6月，该公司在纳斯达克上市。据介绍，Century Therapeutics公司的临床前研发项目包括多种诱导多能干细胞衍生的CAR-iT和CAR-iNK细胞产品，拟开发用于治疗血液癌症和实体瘤。其中，候选药物CNTY-101是一种同种异体、iPSC衍生的CAR-iNK细胞疗法，拟开发用于治疗复发性/难治性B细胞淋巴瘤。候选药物CNTY-103为靶向CD133/EGFR的CAR-iNK候选物，拟用于治疗复发性胶质母细胞瘤（GBM）。此外，该公司还在开发用于治疗复发性/难治性B细胞淋巴瘤、急性髓系白血病（AML）等疾病的候选药物。\n3、Lyell Immunopharma\n研究领域：细胞治疗\nLyell Immunopharma旨在通过对T细胞进行“重编程”（reprogramming），开发具有“治愈”潜力的实体瘤T细胞疗法。2021年6月，该公司正式登陆纳斯达克。Lyell公司认为，T细胞疗法在治疗实体瘤治疗方面主要面临两大障碍：一是，T细胞耗竭导致其失去杀伤肿瘤细胞的功能；二是，T细胞的干细胞特征不够持久，导致T细胞疗法的持续增殖和更新能力有限。Lyell公司正在应用其专有的离体遗传和表观遗传重编程技术平台Gen-R和Epi-R来解决这些障碍，以开发创新疗法。据介绍，Lyell公司开发的LYL797是一款靶向ROR1抗原的在研CAR-T疗法，该产品添加了一个基于优化的表皮生长因子受体（EGFR）的安全开关，拟开发用于治疗表达ROR1的非小细胞肺癌、三阴性乳腺癌等癌症。另一款候选产品LYL845是一种自体肿瘤浸润淋巴细胞（TIL）疗法，有望治疗多种实体瘤。此外，该公司还在与葛兰素史克（GSK）合作开发靶向NY-ESO-1的TCR-T细胞疗法。\n4、Talaris Therapeutics\n研究领域：细胞治疗\nTalaris Therapeutics致力于开发通过一次性细胞疗法的治疗，永久性解决器官移植患者需要接受长期免疫抑制疗法的难题。2021年5月，该公司在纳斯达克上市。长期服用免疫抑制药物的副作用，让Talaris公司的创始人Suzanne Ildstad博士决心开发一种提高机体免疫耐受力的创新疗法。她的研究发现骨髓中存在一种促进细胞（facilitating cell），这些细胞与干细胞不同，它们能够帮助移植到宿主体内的干细胞迁移到骨髓中，在那里生成免疫细胞和其它血细胞。此外，促进细胞还能够增强宿主的免疫耐受能力，降低移植物抗宿主病（GVHD）产生的风险。据介绍，Talaris公司开发的在研细胞疗法FCR001已进入后期临床试验阶段，拟开发治疗以前接受活体供体肾脏移植的患者、重度自身免疫性疾病患者等。此前，FDA已授予FCR001孤儿药资格和再生医学先进疗法认定（RMAT）。\n5、兆科眼科\n研究领域：眼科创新药\n兆科眼科致力于发现、开发及商业化眼科疗法。通过自主开发或许可引进，兆科眼科已建立起一条包含25种候选药物（包含13种创新药和12种仿制药）的全面眼科药物管线，涵盖影响眼前节及眼后节的多数主要眼科适应症。2021年4月，兆科眼科正式在港交所上市。\n\n据悉，兆科眼科初步研发重心聚焦中国五大眼科适应症上，即干眼症(DED)、湿性老年黄斑部病变(wAMD)、糖尿病黄斑水肿(DME)、近视眼以及青光眼。由于存在多种病理过程，许多眼科疾病的发展分多个阶段。因此，大部分眼科疾病属于异质性疾病。对于不同的眼科适应症，兆科眼科的开发策略是选择开发具有不同作用机制的多种候选药物，希望通过单一疗法或联合给药，给患者带来灵活的治疗选择。\n6、Design Therapeutics\n研究领域：自身免疫疾病\nDesign Therapeutics致力于开发治疗由核苷酸重复序列扩增引起的严重退行性疾病的药物，该公司于2021年3月在纳斯达克上市。核苷酸重复序列疾病是由基因的某些短序列重复扩增而引起的一类遗传性疾病。根据其所处位置，重复序列可能会导致基因表达调控的改变或产生有毒的基因产物，它们被认为是造成退行性疾病的重要因素。\n根据Design Therapeutics官网，该公司目前有两个主要研究项目。其中一个研究项目针对的适应症为Friedreich共济失调（Friedreich’s ataxia，FA）患者。FA是一种最常见的遗传性共济失调类型，由于FXN基因的突变，限制了共济蛋白（frataxin）的产生，进而导致各种衰弱的症状和并发症。另一个研究项目针对的适应症为强直性肌营养不良1型(myotonic dystrophy type-1，DM1)。DM1是一种单基因、常染色体显性遗传、进行性神经肌肉疾病，由DMPK基因突变引起，影响骨骼肌、心脏、大脑和其他器官。该病的主要特征包括肌肉无力、肌强直（肌肉松弛缓慢）和早期白内障。此外，受影响的个体经常会出现心律失常和神经心理功能的变化。\n7、Instil Bio\n研究领域：细胞治疗\nInstil Bio是一家全球性的临床阶段细胞疗法公司，致力于开发治疗癌症的肿瘤浸润淋巴细胞疗法，该公司于2021年3月在纳斯达克上市。Instil Bio官网信息显示，该公司研究进度最快的在研产品为ITIL-168，其治疗晚期黑色素瘤的临床试验已处于1期临床试验阶段。此外，ITIL-168还拟被开发用于治疗皮肤鳞状细胞癌（CSCC）、非小细胞肺癌（NSCLC）和宫颈癌等适应症。除了上述企业，高瓴投资的纳微科技（研究领域：纳米微球）、时代天使（研究领域：口腔器械）、心通医疗（研究领域：心脏瓣膜）、贝康医疗（研究领域：体外诊断）也已在今年IPO。限于篇幅，本文不再一一介绍。\n就目前来看，2021年高瓴的IPO方向以新一代基因治疗、细胞疗法的创新药为主。就其投资的企业类型来看，创新研发能力强、处于早期阶段的科创企业更受青睐。对于其中大部分项目，高瓴都进行了多轮投资，是这些公司的长期支持者。\n期待这些企业在资本的助力下，可以早日将创新产品推出市场，造福人类健康。","news_type":1,"symbols_score_info":{"02171":0.9,"IPSC":0.9}},"isVote":1,"tweetType":1,"viewCount":4918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153914608,"gmtCreate":1625004466104,"gmtModify":1703849748662,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087745047715700","idStr":"4087745047715700"},"themes":[],"title":"","htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153914608","repostId":"1146206014","repostType":4,"repost":{"id":"1146206014","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624973528,"share":"https://ttm.financial/m/news/1146206014?lang=en_US&edition=fundamental","pubTime":"2021-06-29 21:32","market":"us","language":"zh","title":"Opening: Nasdaq and S&P hit another record high, blockchain sector rose broadly","url":"https://stock-news.laohu8.com/highlight/detail?id=1146206014","media":"老虎资讯综合","summary":"6月29日，美国股市三大指数小幅高开，纳指与标普500指数再创历史新高。截至发稿，道指上涨0.34%，纳指上涨0.06%，标普500指数上涨0.14%。\n区块链板块普涨，Riot Blockchain","content":"<p>On June 29th, the three major indexes of the U.S. stock market opened slightly higher, and the Nasdaq and S&P 500 reached another record high. At press time, the Dow is up 0.34%, the Nasdaq is up 0.06% and the S&P 500 is up 0.14%.</p><p><img src=\"https://static.tigerbbs.com/2e4b11b4f251daeec3a6e30b91c722ad\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">The Blockchain sector rose generally, Riot Blockchain,<a href=\"https://laohu8.com/S/NCTY\">9th City</a>Up more than 5%,<a href=\"https://laohu8.com/S/CAN\">Canaan Technology</a>It rose by more than 3%.</p><p>Most popular Chinese stocks fell,<a href=\"https://laohu8.com/S/NTES\">Netease</a>Youdao fell more than 3%,<a href=\"https://laohu8.com/S/BILI\">Bilibili</a>、<a href=\"https://laohu8.com/S/PDD\">Pinduoduo</a>、<a href=\"https://laohu8.com/S/BIDU\">Baidu</a>、<a href=\"https://laohu8.com/S/BABA\">Alibaba</a>It fell by more than 1%.</p><p><a href=\"https://laohu8.com/S/BA\">boeing</a>Up nearly 2%, United is reported to have ordered several<a href=\"https://laohu8.com/S/BA\">boeing</a>Planes.</p><p><a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>up 3.8% after the company announced it would double its Dividend and increase share buybacks.</p><p>Cloud enterprise marketing Software Marin Software rose 22.67%. The company has gained nearly 340% in the past three days. On the news, the company announced that its flagship platform MarinOne has added the ability to manage Instacart ads.</p><p><a href=\"https://laohu8.com/S/HOLI\">Hollysys Automation</a>up 5.56%. The company announced today that a group of buyers comprising CPE Funds Management Limited, Pak-Ching Shao and Ace Lead Profits Limited has sought consent from the company's shareholders for its proposed acquisition of Hollysys Automation.</p><p><a href=\"https://laohu8.com/S/00013\">Hutchison Medicine</a>It fell 1.55%. Today, its Hong Kong stocks closed up about 25% in dark market trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opening: Nasdaq and S&P hit another record high, blockchain sector rose broadly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpening: Nasdaq and S&P hit another record high, blockchain sector rose broadly\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-29 21:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On June 29th, the three major indexes of the U.S. stock market opened slightly higher, and the Nasdaq and S&P 500 reached another record high. At press time, the Dow is up 0.34%, the Nasdaq is up 0.06% and the S&P 500 is up 0.14%.</p><p><img src=\"https://static.tigerbbs.com/2e4b11b4f251daeec3a6e30b91c722ad\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">The Blockchain sector rose generally, Riot Blockchain,<a href=\"https://laohu8.com/S/NCTY\">9th City</a>Up more than 5%,<a href=\"https://laohu8.com/S/CAN\">Canaan Technology</a>It rose by more than 3%.</p><p>Most popular Chinese stocks fell,<a href=\"https://laohu8.com/S/NTES\">Netease</a>Youdao fell more than 3%,<a href=\"https://laohu8.com/S/BILI\">Bilibili</a>、<a href=\"https://laohu8.com/S/PDD\">Pinduoduo</a>、<a href=\"https://laohu8.com/S/BIDU\">Baidu</a>、<a href=\"https://laohu8.com/S/BABA\">Alibaba</a>It fell by more than 1%.</p><p><a href=\"https://laohu8.com/S/BA\">boeing</a>Up nearly 2%, United is reported to have ordered several<a href=\"https://laohu8.com/S/BA\">boeing</a>Planes.</p><p><a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>up 3.8% after the company announced it would double its Dividend and increase share buybacks.</p><p>Cloud enterprise marketing Software Marin Software rose 22.67%. The company has gained nearly 340% in the past three days. On the news, the company announced that its flagship platform MarinOne has added the ability to manage Instacart ads.</p><p><a href=\"https://laohu8.com/S/HOLI\">Hollysys Automation</a>up 5.56%. The company announced today that a group of buyers comprising CPE Funds Management Limited, Pak-Ching Shao and Ace Lead Profits Limited has sought consent from the company's shareholders for its proposed acquisition of Hollysys Automation.</p><p><a href=\"https://laohu8.com/S/00013\">Hutchison Medicine</a>It fell 1.55%. Today, its Hong Kong stocks closed up about 25% in dark market trading.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","relate_stocks":{".IXIC":"NASDAQ Composite","QID":"两倍做空纳斯达克指数ETF-ProShares","PSQ":"做空纳斯达克100指数ETF-ProShares","QQQ":"纳指100ETF","TQQQ":"纳指三倍做多ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares","SQQQ":"纳指三倍做空ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯","03086":"华夏纳指"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146206014","content_text":"6月29日，美国股市三大指数小幅高开，纳指与标普500指数再创历史新高。截至发稿，道指上涨0.34%，纳指上涨0.06%，标普500指数上涨0.14%。\n区块链板块普涨，Riot Blockchain、第九城市涨超5%，嘉楠科技涨超3%。\n多数热门中概股走低，网易有道跌逾3%，哔哩哔哩、拼多多、百度、阿里巴巴跌超1%。\n波音涨近2%，据悉美联航订购了数辆波音飞机。\n摩根士丹利涨3.8%，此前公司宣布将股息加倍，并增加股票回购。\n云企业营销软件Marin Software涨22.67%。该公司近三日累计涨幅近340%。消息面上，公司宣布其旗舰平台MarinOne增加了管理Instacart广告的能力。\n和利时自动化涨5.56%。该公司今日宣布，由CPE Funds Management Limited、邵柏庆及Ace Lead Profits Limited组成的买方团就其对和利时自动化的拟议收购，向公司股东征求同意。\n和黄医药跌1.55%，今日其港股暗盘交易收涨约25%。","news_type":1,"symbols_score_info":{"TQQQ":0.9,"QLD":0.9,".IXIC":0.9,"ESmain":0.9,"QID":0.9,"03086":0.9,"MNQmain":0.9,"SQQQ":0.9,".DJI":0.9,"NQmain":0.9,"PSQ":0.9,".SPX":0.9,"QQQ":0.9}},"isVote":1,"tweetType":1,"viewCount":5818,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153914035,"gmtCreate":1625004421927,"gmtModify":1703849748166,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087745047715700","idStr":"4087745047715700"},"themes":[],"title":"","htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153914035","repostId":"2147904866","repostType":4,"isVote":1,"tweetType":1,"viewCount":4063,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153915947,"gmtCreate":1625004310889,"gmtModify":1703849746528,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087745047715700","idStr":"4087745047715700"},"themes":[],"title":"","htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153915947","repostId":"2147468863","repostType":4,"isVote":1,"tweetType":1,"viewCount":4730,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153913013,"gmtCreate":1625003795032,"gmtModify":1703849739461,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087745047715700","idStr":"4087745047715700"},"themes":[],"title":"","htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153913013","repostId":"1106873810","repostType":4,"repost":{"id":"1106873810","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624989419,"share":"https://ttm.financial/m/news/1106873810?lang=en_US&edition=fundamental","pubTime":"2021-06-30 01:56","market":"us","language":"zh","title":"Ding Dong Maicai officially landed on NYSE and opened 21% on the first day","url":"https://stock-news.laohu8.com/highlight/detail?id=1106873810","media":"老虎资讯综合","summary":"北京时间6月30日，叮咚买菜正式登陆纽交所，首日开涨21%，此前给出的IPO发行价为每份ADS 23.50美元。\n\n上市前夕发行规模缩减7成\n叮咚买菜在上市前夜紧急更新了IPO招股书，据最新招股书显示","content":"<p>On June 30th, Beijing time, Ding Dong Maicai officially landed on the New York Stock Exchange, rising by 21% on the first day. The previous IPO issue price was $23.50 per ADS.</p><p><img src=\"https://static.tigerbbs.com/8019015b6d73a8f99bab4121482e7be7\" tg-width=\"827\" tg-height=\"595\" referrerpolicy=\"no-referrer\"></p><p><b>On the eve of listing, the issuance scale was reduced by 70%</b></p><p>Dingdong Maicai urgently updated its IPO prospectus on the eve of its listing. According to the latest prospectus, Dingdong Maicai has reduced its goal of listing and financing in the United States to about a quarter of the original, that is, it seeks to raise up to 94.4 million USD, which is 74% lower than the originally planned financing of 357 million USD. The number of depositary shares (ADS) issued has also been cut from 14 million shares to 3.7 million shares, with a price range of 23.50 USD to 25.50 USD.</p><p>A week ago, Dingdong Maicai's first updated prospectus showed that it would publicly issue 14 million American depositary shares. At that time, it could raise nearly $360 million according to the upper limit of the offering price range. In contrast, the last announced fundraising scale was reduced to a quarter of the previous quota, that is, the overall reduction was over 70%.</p><p><b>About Dingdong Grocery Buying</b></p><p>Dingdong Maicai is headquartered in Shanghai and operates its own grocery app. Consumers can buy fresh food on demand through the \"front warehouse\" network. The so-called front warehouse is a warehouse located close to residential areas according to the established strategy, so as to ensure that Ding Dong's groceries can be delivered to your door within 30 minutes as promised. Their services have now covered a range of major cities such as Shanghai, Beijing, Shenzhen and Hangzhou.</p><p>Ding Dong Maicai was born in 2017. Liang Changlin, the founder and CEO, had many successful entrepreneurial experiences before, so it quickly attracted the support of a series of venture capital, including Sequoia China and Qiming Venture Capital. In addition, such as Tiger Global, Gaorong Capital and Dachen Caizhi were also among the shareholders of the company. With the support of strong capital, it took Ding Dong only seven months to buy groceries, and the number of its front warehouses tripled to 345.</p><p>According to reports, in February 2020, against the background of the outbreak of COVID-19, Dingdong Maicai had to execute about 300,000 orders every day in Shanghai, and the company's total revenue that year also reached about 1.7 billion US dollars. As of January 2021, Dingdong Maicai's business has covered nearly 30 cities across the country, with about 1,000 front-end warehouses and a monthly user base of about 6.9 million.</p><p>In this field, the main competitors of Dingdong Maicai include Alibaba's Box Horse, Meituan Maicai, Daily Youxian and JD.COM Daojia.</p><p><b>Financial Performance</b></p><p>The recent financial performance of Dingdong Maicai can be roughly summarized as follows: the revenue has grown rapidly, but it is suspected to have peaked; Operating losses and net losses continued to expand, and the net loss ratio fluctuated; The burning of money is considerable, and the free cash flow is still negative.</p><p>Specifically, in 2020, Dingdong's grocery revenue reached 11.336 billion yuan, a 192.16% increase from 3.88 billion yuan in 2019. In the first quarter of 2021, the company's revenue was 3.802 billion yuan, a year-on-year increase of 46.01%.</p><p>In 2020, Dingdong Maicai's operating loss was RMB3.162 billion, representing an increase of 78.42% from RMB1.741 billion in 2019. In the first quarter of 2021, the company's operating loss was RMB1.334 billion, representing a year-on-year increase of 352.20%.</p><p>In 2020, Dingdong Maicai's net loss was RMB3.175 billion, an increase of 69.51% from RMB1.873 billion in 2019. In the first quarter of 2021, the company's net loss was RMB1.385 billion, an increase of 465.31% year-on-year.</p><p>In 2020, the net loss rate of Dingdong Maicai was 28.0%, which was significantly lower than 48.3% in 2019. However, in the first quarter of 2021, the net loss rate soared from 9.4% in the same period of the previous year to 36.4%.</p><p>As of March 31, 2021, Dingdong Maicai had total liabilities of US$898 million and cash and equivalents held of US$973 million. For the twelve months ended March 31, 2021, the Company's free cash flow was-$155 million.</p><p><b>Analysis Comments</b></p><p>According to the established strategy, the profit of Dingdong Maicai mainly comes from the sales of fresh food and other commodities completed through app. However, at present, they are far from achieving profitability, and they can't see a clear roadmap, so that the front warehouse model itself adopted by Dingdong Maicai and other competitors is questioned by market observers from time to time.</p><p>So far, Ding Dong has failed to achieve profitability, and from the financial data, their losses even have the momentum of expanding, and there is no clear profit prospect at all.</p><p>Although the market where Ding Dong groceries is located has a bright future in theory, the fierce competition and low profit margins here are well known. For example, it is reported that the order execution cost of Ding Dong's grocery purchase, including distribution fee, packaging fee, logistics cost, etc., will be twice the net revenue of the order itself in 2020.</p><p>This means that no matter how the number of orders of the company grows, it is not enough for Ding Dong to turn losses into profits in a short time, because the fact is that the more orders, the greater the loss. In fact, the front warehouse mode itself is a \"gold-swallowing beast\", and it is already a severe challenge for the company to control the burning speed of this mode.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ding Dong Maicai officially landed on NYSE and opened 21% on the first day</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDing Dong Maicai officially landed on NYSE and opened 21% on the first day\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-30 01:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On June 30th, Beijing time, Ding Dong Maicai officially landed on the New York Stock Exchange, rising by 21% on the first day. The previous IPO issue price was $23.50 per ADS.</p><p><img src=\"https://static.tigerbbs.com/8019015b6d73a8f99bab4121482e7be7\" tg-width=\"827\" tg-height=\"595\" referrerpolicy=\"no-referrer\"></p><p><b>On the eve of listing, the issuance scale was reduced by 70%</b></p><p>Dingdong Maicai urgently updated its IPO prospectus on the eve of its listing. According to the latest prospectus, Dingdong Maicai has reduced its goal of listing and financing in the United States to about a quarter of the original, that is, it seeks to raise up to 94.4 million USD, which is 74% lower than the originally planned financing of 357 million USD. The number of depositary shares (ADS) issued has also been cut from 14 million shares to 3.7 million shares, with a price range of 23.50 USD to 25.50 USD.</p><p>A week ago, Dingdong Maicai's first updated prospectus showed that it would publicly issue 14 million American depositary shares. At that time, it could raise nearly $360 million according to the upper limit of the offering price range. In contrast, the last announced fundraising scale was reduced to a quarter of the previous quota, that is, the overall reduction was over 70%.</p><p><b>About Dingdong Grocery Buying</b></p><p>Dingdong Maicai is headquartered in Shanghai and operates its own grocery app. Consumers can buy fresh food on demand through the \"front warehouse\" network. The so-called front warehouse is a warehouse located close to residential areas according to the established strategy, so as to ensure that Ding Dong's groceries can be delivered to your door within 30 minutes as promised. Their services have now covered a range of major cities such as Shanghai, Beijing, Shenzhen and Hangzhou.</p><p>Ding Dong Maicai was born in 2017. Liang Changlin, the founder and CEO, had many successful entrepreneurial experiences before, so it quickly attracted the support of a series of venture capital, including Sequoia China and Qiming Venture Capital. In addition, such as Tiger Global, Gaorong Capital and Dachen Caizhi were also among the shareholders of the company. With the support of strong capital, it took Ding Dong only seven months to buy groceries, and the number of its front warehouses tripled to 345.</p><p>According to reports, in February 2020, against the background of the outbreak of COVID-19, Dingdong Maicai had to execute about 300,000 orders every day in Shanghai, and the company's total revenue that year also reached about 1.7 billion US dollars. As of January 2021, Dingdong Maicai's business has covered nearly 30 cities across the country, with about 1,000 front-end warehouses and a monthly user base of about 6.9 million.</p><p>In this field, the main competitors of Dingdong Maicai include Alibaba's Box Horse, Meituan Maicai, Daily Youxian and JD.COM Daojia.</p><p><b>Financial Performance</b></p><p>The recent financial performance of Dingdong Maicai can be roughly summarized as follows: the revenue has grown rapidly, but it is suspected to have peaked; Operating losses and net losses continued to expand, and the net loss ratio fluctuated; The burning of money is considerable, and the free cash flow is still negative.</p><p>Specifically, in 2020, Dingdong's grocery revenue reached 11.336 billion yuan, a 192.16% increase from 3.88 billion yuan in 2019. In the first quarter of 2021, the company's revenue was 3.802 billion yuan, a year-on-year increase of 46.01%.</p><p>In 2020, Dingdong Maicai's operating loss was RMB3.162 billion, representing an increase of 78.42% from RMB1.741 billion in 2019. In the first quarter of 2021, the company's operating loss was RMB1.334 billion, representing a year-on-year increase of 352.20%.</p><p>In 2020, Dingdong Maicai's net loss was RMB3.175 billion, an increase of 69.51% from RMB1.873 billion in 2019. In the first quarter of 2021, the company's net loss was RMB1.385 billion, an increase of 465.31% year-on-year.</p><p>In 2020, the net loss rate of Dingdong Maicai was 28.0%, which was significantly lower than 48.3% in 2019. However, in the first quarter of 2021, the net loss rate soared from 9.4% in the same period of the previous year to 36.4%.</p><p>As of March 31, 2021, Dingdong Maicai had total liabilities of US$898 million and cash and equivalents held of US$973 million. For the twelve months ended March 31, 2021, the Company's free cash flow was-$155 million.</p><p><b>Analysis Comments</b></p><p>According to the established strategy, the profit of Dingdong Maicai mainly comes from the sales of fresh food and other commodities completed through app. However, at present, they are far from achieving profitability, and they can't see a clear roadmap, so that the front warehouse model itself adopted by Dingdong Maicai and other competitors is questioned by market observers from time to time.</p><p>So far, Ding Dong has failed to achieve profitability, and from the financial data, their losses even have the momentum of expanding, and there is no clear profit prospect at all.</p><p>Although the market where Ding Dong groceries is located has a bright future in theory, the fierce competition and low profit margins here are well known. For example, it is reported that the order execution cost of Ding Dong's grocery purchase, including distribution fee, packaging fee, logistics cost, etc., will be twice the net revenue of the order itself in 2020.</p><p>This means that no matter how the number of orders of the company grows, it is not enough for Ding Dong to turn losses into profits in a short time, because the fact is that the more orders, the greater the loss. In fact, the front warehouse mode itself is a \"gold-swallowing beast\", and it is already a severe challenge for the company to control the burning speed of this mode.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8bdbf77f2a44d0a051afa32e60a46fbf","relate_stocks":{"DDL":"叮咚买菜"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106873810","content_text":"北京时间6月30日，叮咚买菜正式登陆纽交所，首日开涨21%，此前给出的IPO发行价为每份ADS 23.50美元。\n\n上市前夕发行规模缩减7成\n叮咚买菜在上市前夜紧急更新了IPO招股书，据最新招股书显示，叮咚买菜将在美国上市融资的目标降低到了原来的四分之一左右，即寻求至多融资9440万美元，比原计划融资的3.57亿美元下降了74%，存托股票(ADS) 发行数量也从1400万股砍到了370万股，价格区间为23.50美元至25.50美元。\n一周前，叮咚买菜首次更新的招股书显示其将公开发行1400万股美国存托股票，彼时按照发行价区间上限计算可筹资达到近3.6亿美元。对比之下，最近一次宣布的募资规模缩减至此前额度的四分之一，即总体缩减幅度超70%。\n关于叮咚买菜\n叮咚买菜总部位于上海，运营着自己的买菜app，消费者可以通过“前置仓”网络购买按需生鲜食品。所谓前置仓，是按照既定策略配置在接近居民区的仓库，确保叮咚买菜能够按照承诺，在三十分钟内送货上门。他们的服务目前已经覆盖了上海、北京、深圳和杭州等一系列主要城市。\n叮咚买菜诞生于2017年，创始人兼首席执行官梁昌霖之前就有多次成功创业的经历，因此很快就吸引了一系列风投资本的支持，包括红杉中国、启明创投等，此外诸如老虎环球、高榕资本、达晨财智等也都在公司股东之列。在雄厚的资本支持下，叮咚买菜只用了七个月时间，就让其前置仓数量增长了三倍，达到了345处。\n据报道，2020年2月，在新冠病毒疫情大爆发的背景下，叮咚买菜在上海每天都要执行大约30万笔订单，公司当年的总营收也达到了大约17亿美元。截至2021年1月，叮咚买菜的业务已经覆盖全国近三十个城市，拥有大约一千家前置仓，每月用户群达到大约690万。\n在这个领域当中，叮咚买菜主要的竞争对手包括阿里巴巴旗下盒马、美团买菜、每日优鲜和京东到家等。\n财务表现\n叮咚买菜近期的财务表现可以大致概括如下：营收高速增长，但疑似已经见顶；运营亏损和净亏损持续扩大，净亏损率起伏不定；烧钱可观，自由现金流依然为负数。\n具体而言，2020年当中，叮咚买菜营收达到113.36亿元人民币，较之2019年的38.80亿元猛增192.16%，2021年第一季度，公司营收38.02亿元，同比增长46.01%。\n2020年当中，叮咚买菜运营亏损31.62亿元人民币，较之2019年的17.41亿元扩大78.42%，2021年第一季度，公司运营亏损13.34亿元，同比扩大352.20%。\n2020年当中，叮咚买菜净亏损31.75亿元人民币，较之2019年的18.73亿元扩大69.51%，2021年第一季度，公司净亏损13.85亿元，同比扩大465.31%。\n2020年当中，叮咚买菜净亏损率28.0%，较之2019年的48.3%大幅降低，但是2021年第一季度，净亏损率又从前一年同期的9.4%猛增到了36.4%。\n截至2021年3月31日，叮咚买菜总负债8.98亿美元，持有现金及等价物9.73亿美元。截至2021年3月31日的十二个月当中，公司自由现金流-1.55亿美元。\n分析评论\n按照既定策略，叮咚买菜的利润主要是来自于通过app完成的生鲜食品和其他各种商品的销售，只是目前，他们还远没有到实现盈利的地步，也看不到清晰的路线图，以至于叮咚买菜和其他竞争对手所采用的前置仓模式本身，都不时受到市场观察家们的质疑。\n迄今为止，叮咚买菜都未能实现盈利，而且从财务数据看，他们的亏损甚至还有扩大的势头，根本看不到明确的盈利前景。\n叮咚买菜所在的市场虽然理论上说来前途远大，但是这里的竞争之激烈和利润率之低也是人尽皆知。比如据报道，叮咚买菜的订单执行成本包括配送费、包装费、物流成本等在内，在2020年内要两倍于订单本身的净营收。\n这也就意味着，不管公司的订单数量如何增长，都不足以让叮咚买菜在短期之内扭亏为盈，因为事实就是，订单越多，亏损越大。事实上，前置仓模式本身就是一头“吞金兽”，要控制这种模式的烧钱速度，已经是摆在公司面前的严峻挑战。","news_type":1,"symbols_score_info":{"DDL":0.9}},"isVote":1,"tweetType":1,"viewCount":4816,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150382948,"gmtCreate":1624887514184,"gmtModify":1703847058280,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087745047715700","idStr":"4087745047715700"},"themes":[],"title":"","htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150382948","repostId":"1187387694","repostType":4,"repost":{"id":"1187387694","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624883343,"share":"https://ttm.financial/m/news/1187387694?lang=en_US&edition=fundamental","pubTime":"2021-06-28 20:29","market":"us","language":"zh","title":"Premarket: Surge 54%! Goldman Sachs \"Crazy Singing More\" a gene compilation company","url":"https://stock-news.laohu8.com/highlight/detail?id=1187387694","media":"老虎资讯综合","summary":"6月28日，美国三大股指期货涨跌不一，截至发稿，道指期货跌0.15%；标普500指数期货涨0.03%；纳斯达克100指数期货涨0.28%。市场要闻\nSK海力士收购英特尔NAND闪存业务在英获准；\n宁德","content":"<p>On June 28th, the three major stock index futures in the United States were mixed. As of press time, the Dow futures fell by 0.15%; S&P 500 futures rose 0.03%; Nasdaq 100 futures rose 0.28%.<img src=\"https://static.tigerbbs.com/27239c4752cec4972e9cdc206e599e87\" tg-width=\"828\" tg-height=\"234\" referrerpolicy=\"no-referrer\"><b>Market News</b></p><p>SK Hynix Acquisition<a href=\"https://laohu8.com/S/INTC\">Intel</a>NAND flash memory business approved in the UK;</p><p><a href=\"https://laohu8.com/S/300750\">CATL</a>: From January 2022 to December 2025, to<a href=\"https://laohu8.com/S/TSLA\">Tesla</a>Supply of lithium-ion power battery products;</p><p>Huawei speaks again: it will not invest and control any car company;</p><p><a href=\"https://laohu8.com/S/AAPL\">Apple</a>China Customer Service Responds to iPhone 12 Mini Discontinuation: No Discontinuation Notice Received;</p><p>Daimler on track to spin off its truck division and list it before year end;</p><p>FAA says<a href=\"https://laohu8.com/S/BA\">boeing</a>The 777X may not be certified until the end of 2023.</p><p><b>Premarket Quotes</b></p><p>Gene compilation company Intellia Therapeutics (NTLA.US) rose more than 54% before the market. Intellia Therapeutics and Regeneron Pharmaceuticals (REGN.US) jointly announced that the CRISPR in vivo genome editing therapy NTLA-2001 under development has achieved positive results in a phase 1 clinical trial. A single dose of NTLA-2001 resulted in a mean 87% decrease in serum transthyretin levels (TTR), with a maximum of 96% decrease in TTR on day 28.<b>Several major banks raised their price targets on the company, including<a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a>And H.C. Wainwright raised its price targets to $163 and $171, respectively.</b></p><p><img src=\"https://static.tigerbbs.com/46fcf6b7e014c960f4578a887dd3bbd3\" tg-width=\"855\" tg-height=\"647\" referrerpolicy=\"no-referrer\"><a href=\"https://laohu8.com/S/CCL\">Carnival Cruises</a>Down 2.4% premarket, will sell $50 million worth of shares.</p><p><a href=\"https://laohu8.com/S/LU\">Lufax</a>Before the market fell more than 3%, market news: Lufax will pass through block trading<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>Sold 49.4 million shares at $11.95 to $12.10 per share.</p><p>The U.S. Blockchain concept sector strengthened before the market, with Marathon Patent and Riot Blockchain rising by more than 3%.<a href=\"https://laohu8.com/S/NCTY\">9th City</a>、<a href=\"https://laohu8.com/S/CAN\">Canaan Technology</a>It rose more than 2%. Bitcoin stood at $35,000/coin, and the 24-hour increase expanded to 4.5%.</p><p>Some Chinese online education concept stocks rose before the market,<a href=\"https://laohu8.com/S/GOTU\">Gaotu</a>rose by more than 2%,<a href=\"https://laohu8.com/S/LAIX\">Fluency theory</a>、<a href=\"https://laohu8.com/S/EDU\">New Oriental</a>、<a href=\"https://laohu8.com/S/TAL\">TAL</a>It rose more than 1%.</p><p><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a>It rose by more than 6% before the market. On the news, the company obtained a full commercial launch license from the Federal Aviation Administration, which can send customers into space. At the same time,<a href=\"https://laohu8.com/S/BCS\">Barclays Bank</a>Analysts raised their price target to $31 from $27.</p><p>Boeing fell 1.3% premarket after the Federal Aviation Administration raised safety concerns about the 777X aircraft.</p><p>Biopharmaceutical company Syndax rose more than 5% before the market. Market news: Syndax's drug was designated as a \"fast track\" for leukemia treatment by the U.S. Food and Drug Administration.</p><p>Biopharmaceutical companies<a href=\"https://laohu8.com/S/CBIO\">Catalyst Biosciences</a>It rose more than 5% before the market, market news: Catalyst Biosciences bleeding treatment drug obtained the rapid approval channel of the U.S. Food and Drug Administration.</p><p>U.S. biotech company Atossa Therapeutis (ATOS.O) fell more than 12% premarket, with a cumulative gain of 807% so far this year.</p><p><b>European market</b></p><p>Major European stock indexes were mixed. As of press time, Germany's DAX30 index rose 0.12%,<a href=\"https://laohu8.com/S/VUKE.UK\">FTSE 100 UK</a>down 0.38%, and French CAC40 fell 0.31%.<img src=\"https://static.tigerbbs.com/1cf9b5bf6bb8e6d32bdb059c9c5bab02\" tg-width=\"826\" tg-height=\"354\" referrerpolicy=\"no-referrer\"><b>crude oil</b></p><p>U.S. and Brunei oil fell. As of press time, WTI crude oil fell 0.23% to $73.87/barrel; Brent crude oil fell 0.32% to $75.13/barrel.</p><p>As the U.S. and Iran battle over restarting the nuclear deal, delaying a surge in Iranian oil exports, investors focus on the outcome of this week's OPEC + meeting, which analyses expect rising oil prices will make it easier for OPEC + to reach an agreement at its ministerial meeting on July 1, when OPEC + will decide on its production-cutting strategy starting in August.</p><p><b>Gold</b></p><p>Spot gold fluctuated during the day, and as of press time, it fell 0.11% to $1,775.85/oz.</p><p>The spot gold price maintains the trend of range shock consolidation. After the Federal Reserve's resolution to release the hawkish tone this month, the gold price plummeted, the market began to look for more clues about the change of the Fed's tone. This week, the market ushered in the June non-farm payrolls report, the highlight of U.S. economic data. I believe this report will bring great fluctuations to the gold market.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Premarket: Surge 54%! Goldman Sachs \"Crazy Singing More\" a gene compilation company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPremarket: Surge 54%! Goldman Sachs \"Crazy Singing More\" a gene compilation company\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-28 20:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On June 28th, the three major stock index futures in the United States were mixed. As of press time, the Dow futures fell by 0.15%; S&P 500 futures rose 0.03%; Nasdaq 100 futures rose 0.28%.<img src=\"https://static.tigerbbs.com/27239c4752cec4972e9cdc206e599e87\" tg-width=\"828\" tg-height=\"234\" referrerpolicy=\"no-referrer\"><b>Market News</b></p><p>SK Hynix Acquisition<a href=\"https://laohu8.com/S/INTC\">Intel</a>NAND flash memory business approved in the UK;</p><p><a href=\"https://laohu8.com/S/300750\">CATL</a>: From January 2022 to December 2025, to<a href=\"https://laohu8.com/S/TSLA\">Tesla</a>Supply of lithium-ion power battery products;</p><p>Huawei speaks again: it will not invest and control any car company;</p><p><a href=\"https://laohu8.com/S/AAPL\">Apple</a>China Customer Service Responds to iPhone 12 Mini Discontinuation: No Discontinuation Notice Received;</p><p>Daimler on track to spin off its truck division and list it before year end;</p><p>FAA says<a href=\"https://laohu8.com/S/BA\">boeing</a>The 777X may not be certified until the end of 2023.</p><p><b>Premarket Quotes</b></p><p>Gene compilation company Intellia Therapeutics (NTLA.US) rose more than 54% before the market. Intellia Therapeutics and Regeneron Pharmaceuticals (REGN.US) jointly announced that the CRISPR in vivo genome editing therapy NTLA-2001 under development has achieved positive results in a phase 1 clinical trial. A single dose of NTLA-2001 resulted in a mean 87% decrease in serum transthyretin levels (TTR), with a maximum of 96% decrease in TTR on day 28.<b>Several major banks raised their price targets on the company, including<a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a>And H.C. Wainwright raised its price targets to $163 and $171, respectively.</b></p><p><img src=\"https://static.tigerbbs.com/46fcf6b7e014c960f4578a887dd3bbd3\" tg-width=\"855\" tg-height=\"647\" referrerpolicy=\"no-referrer\"><a href=\"https://laohu8.com/S/CCL\">Carnival Cruises</a>Down 2.4% premarket, will sell $50 million worth of shares.</p><p><a href=\"https://laohu8.com/S/LU\">Lufax</a>Before the market fell more than 3%, market news: Lufax will pass through block trading<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>Sold 49.4 million shares at $11.95 to $12.10 per share.</p><p>The U.S. Blockchain concept sector strengthened before the market, with Marathon Patent and Riot Blockchain rising by more than 3%.<a href=\"https://laohu8.com/S/NCTY\">9th City</a>、<a href=\"https://laohu8.com/S/CAN\">Canaan Technology</a>It rose more than 2%. Bitcoin stood at $35,000/coin, and the 24-hour increase expanded to 4.5%.</p><p>Some Chinese online education concept stocks rose before the market,<a href=\"https://laohu8.com/S/GOTU\">Gaotu</a>rose by more than 2%,<a href=\"https://laohu8.com/S/LAIX\">Fluency theory</a>、<a href=\"https://laohu8.com/S/EDU\">New Oriental</a>、<a href=\"https://laohu8.com/S/TAL\">TAL</a>It rose more than 1%.</p><p><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a>It rose by more than 6% before the market. On the news, the company obtained a full commercial launch license from the Federal Aviation Administration, which can send customers into space. At the same time,<a href=\"https://laohu8.com/S/BCS\">Barclays Bank</a>Analysts raised their price target to $31 from $27.</p><p>Boeing fell 1.3% premarket after the Federal Aviation Administration raised safety concerns about the 777X aircraft.</p><p>Biopharmaceutical company Syndax rose more than 5% before the market. Market news: Syndax's drug was designated as a \"fast track\" for leukemia treatment by the U.S. Food and Drug Administration.</p><p>Biopharmaceutical companies<a href=\"https://laohu8.com/S/CBIO\">Catalyst Biosciences</a>It rose more than 5% before the market, market news: Catalyst Biosciences bleeding treatment drug obtained the rapid approval channel of the U.S. Food and Drug Administration.</p><p>U.S. biotech company Atossa Therapeutis (ATOS.O) fell more than 12% premarket, with a cumulative gain of 807% so far this year.</p><p><b>European market</b></p><p>Major European stock indexes were mixed. As of press time, Germany's DAX30 index rose 0.12%,<a href=\"https://laohu8.com/S/VUKE.UK\">FTSE 100 UK</a>down 0.38%, and French CAC40 fell 0.31%.<img src=\"https://static.tigerbbs.com/1cf9b5bf6bb8e6d32bdb059c9c5bab02\" tg-width=\"826\" tg-height=\"354\" referrerpolicy=\"no-referrer\"><b>crude oil</b></p><p>U.S. and Brunei oil fell. As of press time, WTI crude oil fell 0.23% to $73.87/barrel; Brent crude oil fell 0.32% to $75.13/barrel.</p><p>As the U.S. and Iran battle over restarting the nuclear deal, delaying a surge in Iranian oil exports, investors focus on the outcome of this week's OPEC + meeting, which analyses expect rising oil prices will make it easier for OPEC + to reach an agreement at its ministerial meeting on July 1, when OPEC + will decide on its production-cutting strategy starting in August.</p><p><b>Gold</b></p><p>Spot gold fluctuated during the day, and as of press time, it fell 0.11% to $1,775.85/oz.</p><p>The spot gold price maintains the trend of range shock consolidation. After the Federal Reserve's resolution to release the hawkish tone this month, the gold price plummeted, the market began to look for more clues about the change of the Fed's tone. This week, the market ushered in the June non-farm payrolls report, the highlight of U.S. economic data. I believe this report will bring great fluctuations to the gold market.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯","GS":"高盛",".IXIC":"NASDAQ Composite","BA":"波音"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187387694","content_text":"6月28日，美国三大股指期货涨跌不一，截至发稿，道指期货跌0.15%；标普500指数期货涨0.03%；纳斯达克100指数期货涨0.28%。市场要闻\nSK海力士收购英特尔NAND闪存业务在英获准；\n宁德时代：2022年1月至2025年12月，将向特斯拉供应锂离子动力电池产品；\n华为再发声：不会投资和控股任何一家车企；\n苹果中国客服回应iPhone 12 Mini停产：未收到停产通知；\n戴姆勒有望年底前将卡车部门分拆上市；\nFAA称波音777X客机可能要到2023年底才能获得认证。\n盘前行情\n基因编译公司Intellia Therapeutics(NTLA.US)盘前涨超54%。Intellia Therapeutics和再生元制药(REGN.US)联合宣布，在研CRISPR体内基因组编辑疗法NTLA-2001在1期临床试验中获得积极结果。单剂NTLA-2001导致血清中的转甲状腺素蛋白水平(TTR)平均下降87%，在第28天TTR降低幅度最大可达96%。多家大行上调对该公司的目标价，其中高盛和H.C. Wainwright分别将其目标价上调至163美元和171美元。\n嘉年华邮轮盘前跌2.4%，将出售价值5000万美元的股票。\n陆金所盘前跌超3%，市场消息：陆金所将通过大宗交易经由摩根士丹利以每股11.95至12.10美元的价格出售4940万股股票。\n美股区块链概念板块盘前走强，Marathon Patent、Riot Blockchain涨超3%，第九城市、嘉楠科技涨超2%。比特币站上35000美元/枚，24小时涨幅扩大至4.5%。\n部分中概在线教育概念股盘前上涨，高途涨超2%，流利说、新东方、好未来涨超1%。\n维珍银河盘前涨超6%，消息面上，公司获美国联邦航空管理局的全面商业发射许可，可将客户送入太空。同时，巴克莱银行分析师将其目标价从27美元上调至31美元。\n波音盘前跌1.3%，此前美国联邦航空管理局对777X飞机提出安全担忧。\n生物制药公司Syndax盘前涨超5%，市场消息：Syndax的药物获得美国食品药品监督管理局白血病治疗“快速通道”指定。\n生物制药公司Catalyst Biosciences盘前涨超5%，市场消息：Catalyst Biosciences出血治疗药物获得美国食品药品监督管理局的快速审批通道。\n美国生物科技公司Atossa Therapeutis(ATOS.O)盘前跌超12%，今年迄今累计涨幅为807%。\n欧洲市场\n欧洲主要股指涨跌不一，截至发稿，德国DAX30指数涨0.12%，英国富时100跌0.38%、法国CAC40跌0.31%。原油\n美、布两油下跌，截止发稿，WTI原油跌0.23%，报73.87美元/桶；布伦特原油跌0.32%，报75.13美元/桶。\n美国和伊朗在重启核协议的问题上争论不休，推迟了伊朗石油出口的激增，投资者关注本周OPEC+会议的结果，分析预计油价上涨将使OPEC+在7月1日的部长级会议上更容易达成协议，届时OPEC+将从8月开始决定其减产战略。\n黄金\n现货黄金日内震荡，截止发稿，跌0.11%，报1775.85美元/盎司。\n现货金价维持区间震荡整理的走势，在本月美联储决议释放鹰派基调金价大跌之后，市场开始寻找美联储基调变化的更多线索，本周市场迎来美国经济数据的重头戏6月非农就业报告，相信这份报告会给黄金市场带来大幅度波动。","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"GS":0.9,"BA":0.9}},"isVote":1,"tweetType":1,"viewCount":4897,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":150382948,"gmtCreate":1624887514184,"gmtModify":1703847058280,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087745047715700","authorIdStr":"4087745047715700"},"themes":[],"title":"","htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150382948","repostId":"1187387694","repostType":4,"repost":{"id":"1187387694","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624883343,"share":"https://ttm.financial/m/news/1187387694?lang=en_US&edition=fundamental","pubTime":"2021-06-28 20:29","market":"us","language":"zh","title":"Premarket: Surge 54%! Goldman Sachs \"Crazy Singing More\" a gene compilation company","url":"https://stock-news.laohu8.com/highlight/detail?id=1187387694","media":"老虎资讯综合","summary":"6月28日，美国三大股指期货涨跌不一，截至发稿，道指期货跌0.15%；标普500指数期货涨0.03%；纳斯达克100指数期货涨0.28%。市场要闻\nSK海力士收购英特尔NAND闪存业务在英获准；\n宁德","content":"<p>On June 28th, the three major stock index futures in the United States were mixed. As of press time, the Dow futures fell by 0.15%; S&P 500 futures rose 0.03%; Nasdaq 100 futures rose 0.28%.<img src=\"https://static.tigerbbs.com/27239c4752cec4972e9cdc206e599e87\" tg-width=\"828\" tg-height=\"234\" referrerpolicy=\"no-referrer\"><b>Market News</b></p><p>SK Hynix Acquisition<a href=\"https://laohu8.com/S/INTC\">Intel</a>NAND flash memory business approved in the UK;</p><p><a href=\"https://laohu8.com/S/300750\">CATL</a>: From January 2022 to December 2025, to<a href=\"https://laohu8.com/S/TSLA\">Tesla</a>Supply of lithium-ion power battery products;</p><p>Huawei speaks again: it will not invest and control any car company;</p><p><a href=\"https://laohu8.com/S/AAPL\">Apple</a>China Customer Service Responds to iPhone 12 Mini Discontinuation: No Discontinuation Notice Received;</p><p>Daimler on track to spin off its truck division and list it before year end;</p><p>FAA says<a href=\"https://laohu8.com/S/BA\">boeing</a>The 777X may not be certified until the end of 2023.</p><p><b>Premarket Quotes</b></p><p>Gene compilation company Intellia Therapeutics (NTLA.US) rose more than 54% before the market. Intellia Therapeutics and Regeneron Pharmaceuticals (REGN.US) jointly announced that the CRISPR in vivo genome editing therapy NTLA-2001 under development has achieved positive results in a phase 1 clinical trial. A single dose of NTLA-2001 resulted in a mean 87% decrease in serum transthyretin levels (TTR), with a maximum of 96% decrease in TTR on day 28.<b>Several major banks raised their price targets on the company, including<a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a>And H.C. Wainwright raised its price targets to $163 and $171, respectively.</b></p><p><img src=\"https://static.tigerbbs.com/46fcf6b7e014c960f4578a887dd3bbd3\" tg-width=\"855\" tg-height=\"647\" referrerpolicy=\"no-referrer\"><a href=\"https://laohu8.com/S/CCL\">Carnival Cruises</a>Down 2.4% premarket, will sell $50 million worth of shares.</p><p><a href=\"https://laohu8.com/S/LU\">Lufax</a>Before the market fell more than 3%, market news: Lufax will pass through block trading<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>Sold 49.4 million shares at $11.95 to $12.10 per share.</p><p>The U.S. Blockchain concept sector strengthened before the market, with Marathon Patent and Riot Blockchain rising by more than 3%.<a href=\"https://laohu8.com/S/NCTY\">9th City</a>、<a href=\"https://laohu8.com/S/CAN\">Canaan Technology</a>It rose more than 2%. Bitcoin stood at $35,000/coin, and the 24-hour increase expanded to 4.5%.</p><p>Some Chinese online education concept stocks rose before the market,<a href=\"https://laohu8.com/S/GOTU\">Gaotu</a>rose by more than 2%,<a href=\"https://laohu8.com/S/LAIX\">Fluency theory</a>、<a href=\"https://laohu8.com/S/EDU\">New Oriental</a>、<a href=\"https://laohu8.com/S/TAL\">TAL</a>It rose more than 1%.</p><p><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a>It rose by more than 6% before the market. On the news, the company obtained a full commercial launch license from the Federal Aviation Administration, which can send customers into space. At the same time,<a href=\"https://laohu8.com/S/BCS\">Barclays Bank</a>Analysts raised their price target to $31 from $27.</p><p>Boeing fell 1.3% premarket after the Federal Aviation Administration raised safety concerns about the 777X aircraft.</p><p>Biopharmaceutical company Syndax rose more than 5% before the market. Market news: Syndax's drug was designated as a \"fast track\" for leukemia treatment by the U.S. Food and Drug Administration.</p><p>Biopharmaceutical companies<a href=\"https://laohu8.com/S/CBIO\">Catalyst Biosciences</a>It rose more than 5% before the market, market news: Catalyst Biosciences bleeding treatment drug obtained the rapid approval channel of the U.S. Food and Drug Administration.</p><p>U.S. biotech company Atossa Therapeutis (ATOS.O) fell more than 12% premarket, with a cumulative gain of 807% so far this year.</p><p><b>European market</b></p><p>Major European stock indexes were mixed. As of press time, Germany's DAX30 index rose 0.12%,<a href=\"https://laohu8.com/S/VUKE.UK\">FTSE 100 UK</a>down 0.38%, and French CAC40 fell 0.31%.<img src=\"https://static.tigerbbs.com/1cf9b5bf6bb8e6d32bdb059c9c5bab02\" tg-width=\"826\" tg-height=\"354\" referrerpolicy=\"no-referrer\"><b>crude oil</b></p><p>U.S. and Brunei oil fell. As of press time, WTI crude oil fell 0.23% to $73.87/barrel; Brent crude oil fell 0.32% to $75.13/barrel.</p><p>As the U.S. and Iran battle over restarting the nuclear deal, delaying a surge in Iranian oil exports, investors focus on the outcome of this week's OPEC + meeting, which analyses expect rising oil prices will make it easier for OPEC + to reach an agreement at its ministerial meeting on July 1, when OPEC + will decide on its production-cutting strategy starting in August.</p><p><b>Gold</b></p><p>Spot gold fluctuated during the day, and as of press time, it fell 0.11% to $1,775.85/oz.</p><p>The spot gold price maintains the trend of range shock consolidation. After the Federal Reserve's resolution to release the hawkish tone this month, the gold price plummeted, the market began to look for more clues about the change of the Fed's tone. This week, the market ushered in the June non-farm payrolls report, the highlight of U.S. economic data. I believe this report will bring great fluctuations to the gold market.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Premarket: Surge 54%! Goldman Sachs \"Crazy Singing More\" a gene compilation company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPremarket: Surge 54%! Goldman Sachs \"Crazy Singing More\" a gene compilation company\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-28 20:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On June 28th, the three major stock index futures in the United States were mixed. As of press time, the Dow futures fell by 0.15%; S&P 500 futures rose 0.03%; Nasdaq 100 futures rose 0.28%.<img src=\"https://static.tigerbbs.com/27239c4752cec4972e9cdc206e599e87\" tg-width=\"828\" tg-height=\"234\" referrerpolicy=\"no-referrer\"><b>Market News</b></p><p>SK Hynix Acquisition<a href=\"https://laohu8.com/S/INTC\">Intel</a>NAND flash memory business approved in the UK;</p><p><a href=\"https://laohu8.com/S/300750\">CATL</a>: From January 2022 to December 2025, to<a href=\"https://laohu8.com/S/TSLA\">Tesla</a>Supply of lithium-ion power battery products;</p><p>Huawei speaks again: it will not invest and control any car company;</p><p><a href=\"https://laohu8.com/S/AAPL\">Apple</a>China Customer Service Responds to iPhone 12 Mini Discontinuation: No Discontinuation Notice Received;</p><p>Daimler on track to spin off its truck division and list it before year end;</p><p>FAA says<a href=\"https://laohu8.com/S/BA\">boeing</a>The 777X may not be certified until the end of 2023.</p><p><b>Premarket Quotes</b></p><p>Gene compilation company Intellia Therapeutics (NTLA.US) rose more than 54% before the market. Intellia Therapeutics and Regeneron Pharmaceuticals (REGN.US) jointly announced that the CRISPR in vivo genome editing therapy NTLA-2001 under development has achieved positive results in a phase 1 clinical trial. A single dose of NTLA-2001 resulted in a mean 87% decrease in serum transthyretin levels (TTR), with a maximum of 96% decrease in TTR on day 28.<b>Several major banks raised their price targets on the company, including<a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a>And H.C. Wainwright raised its price targets to $163 and $171, respectively.</b></p><p><img src=\"https://static.tigerbbs.com/46fcf6b7e014c960f4578a887dd3bbd3\" tg-width=\"855\" tg-height=\"647\" referrerpolicy=\"no-referrer\"><a href=\"https://laohu8.com/S/CCL\">Carnival Cruises</a>Down 2.4% premarket, will sell $50 million worth of shares.</p><p><a href=\"https://laohu8.com/S/LU\">Lufax</a>Before the market fell more than 3%, market news: Lufax will pass through block trading<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>Sold 49.4 million shares at $11.95 to $12.10 per share.</p><p>The U.S. Blockchain concept sector strengthened before the market, with Marathon Patent and Riot Blockchain rising by more than 3%.<a href=\"https://laohu8.com/S/NCTY\">9th City</a>、<a href=\"https://laohu8.com/S/CAN\">Canaan Technology</a>It rose more than 2%. Bitcoin stood at $35,000/coin, and the 24-hour increase expanded to 4.5%.</p><p>Some Chinese online education concept stocks rose before the market,<a href=\"https://laohu8.com/S/GOTU\">Gaotu</a>rose by more than 2%,<a href=\"https://laohu8.com/S/LAIX\">Fluency theory</a>、<a href=\"https://laohu8.com/S/EDU\">New Oriental</a>、<a href=\"https://laohu8.com/S/TAL\">TAL</a>It rose more than 1%.</p><p><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a>It rose by more than 6% before the market. On the news, the company obtained a full commercial launch license from the Federal Aviation Administration, which can send customers into space. At the same time,<a href=\"https://laohu8.com/S/BCS\">Barclays Bank</a>Analysts raised their price target to $31 from $27.</p><p>Boeing fell 1.3% premarket after the Federal Aviation Administration raised safety concerns about the 777X aircraft.</p><p>Biopharmaceutical company Syndax rose more than 5% before the market. Market news: Syndax's drug was designated as a \"fast track\" for leukemia treatment by the U.S. Food and Drug Administration.</p><p>Biopharmaceutical companies<a href=\"https://laohu8.com/S/CBIO\">Catalyst Biosciences</a>It rose more than 5% before the market, market news: Catalyst Biosciences bleeding treatment drug obtained the rapid approval channel of the U.S. Food and Drug Administration.</p><p>U.S. biotech company Atossa Therapeutis (ATOS.O) fell more than 12% premarket, with a cumulative gain of 807% so far this year.</p><p><b>European market</b></p><p>Major European stock indexes were mixed. As of press time, Germany's DAX30 index rose 0.12%,<a href=\"https://laohu8.com/S/VUKE.UK\">FTSE 100 UK</a>down 0.38%, and French CAC40 fell 0.31%.<img src=\"https://static.tigerbbs.com/1cf9b5bf6bb8e6d32bdb059c9c5bab02\" tg-width=\"826\" tg-height=\"354\" referrerpolicy=\"no-referrer\"><b>crude oil</b></p><p>U.S. and Brunei oil fell. As of press time, WTI crude oil fell 0.23% to $73.87/barrel; Brent crude oil fell 0.32% to $75.13/barrel.</p><p>As the U.S. and Iran battle over restarting the nuclear deal, delaying a surge in Iranian oil exports, investors focus on the outcome of this week's OPEC + meeting, which analyses expect rising oil prices will make it easier for OPEC + to reach an agreement at its ministerial meeting on July 1, when OPEC + will decide on its production-cutting strategy starting in August.</p><p><b>Gold</b></p><p>Spot gold fluctuated during the day, and as of press time, it fell 0.11% to $1,775.85/oz.</p><p>The spot gold price maintains the trend of range shock consolidation. After the Federal Reserve's resolution to release the hawkish tone this month, the gold price plummeted, the market began to look for more clues about the change of the Fed's tone. This week, the market ushered in the June non-farm payrolls report, the highlight of U.S. economic data. I believe this report will bring great fluctuations to the gold market.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯","GS":"高盛",".IXIC":"NASDAQ Composite","BA":"波音"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187387694","content_text":"6月28日，美国三大股指期货涨跌不一，截至发稿，道指期货跌0.15%；标普500指数期货涨0.03%；纳斯达克100指数期货涨0.28%。市场要闻\nSK海力士收购英特尔NAND闪存业务在英获准；\n宁德时代：2022年1月至2025年12月，将向特斯拉供应锂离子动力电池产品；\n华为再发声：不会投资和控股任何一家车企；\n苹果中国客服回应iPhone 12 Mini停产：未收到停产通知；\n戴姆勒有望年底前将卡车部门分拆上市；\nFAA称波音777X客机可能要到2023年底才能获得认证。\n盘前行情\n基因编译公司Intellia Therapeutics(NTLA.US)盘前涨超54%。Intellia Therapeutics和再生元制药(REGN.US)联合宣布，在研CRISPR体内基因组编辑疗法NTLA-2001在1期临床试验中获得积极结果。单剂NTLA-2001导致血清中的转甲状腺素蛋白水平(TTR)平均下降87%，在第28天TTR降低幅度最大可达96%。多家大行上调对该公司的目标价，其中高盛和H.C. Wainwright分别将其目标价上调至163美元和171美元。\n嘉年华邮轮盘前跌2.4%，将出售价值5000万美元的股票。\n陆金所盘前跌超3%，市场消息：陆金所将通过大宗交易经由摩根士丹利以每股11.95至12.10美元的价格出售4940万股股票。\n美股区块链概念板块盘前走强，Marathon Patent、Riot Blockchain涨超3%，第九城市、嘉楠科技涨超2%。比特币站上35000美元/枚，24小时涨幅扩大至4.5%。\n部分中概在线教育概念股盘前上涨，高途涨超2%，流利说、新东方、好未来涨超1%。\n维珍银河盘前涨超6%，消息面上，公司获美国联邦航空管理局的全面商业发射许可，可将客户送入太空。同时，巴克莱银行分析师将其目标价从27美元上调至31美元。\n波音盘前跌1.3%，此前美国联邦航空管理局对777X飞机提出安全担忧。\n生物制药公司Syndax盘前涨超5%，市场消息：Syndax的药物获得美国食品药品监督管理局白血病治疗“快速通道”指定。\n生物制药公司Catalyst Biosciences盘前涨超5%，市场消息：Catalyst Biosciences出血治疗药物获得美国食品药品监督管理局的快速审批通道。\n美国生物科技公司Atossa Therapeutis(ATOS.O)盘前跌超12%，今年迄今累计涨幅为807%。\n欧洲市场\n欧洲主要股指涨跌不一，截至发稿，德国DAX30指数涨0.12%，英国富时100跌0.38%、法国CAC40跌0.31%。原油\n美、布两油下跌，截止发稿，WTI原油跌0.23%，报73.87美元/桶；布伦特原油跌0.32%，报75.13美元/桶。\n美国和伊朗在重启核协议的问题上争论不休，推迟了伊朗石油出口的激增，投资者关注本周OPEC+会议的结果，分析预计油价上涨将使OPEC+在7月1日的部长级会议上更容易达成协议，届时OPEC+将从8月开始决定其减产战略。\n黄金\n现货黄金日内震荡，截止发稿，跌0.11%，报1775.85美元/盎司。\n现货金价维持区间震荡整理的走势，在本月美联储决议释放鹰派基调金价大跌之后，市场开始寻找美联储基调变化的更多线索，本周市场迎来美国经济数据的重头戏6月非农就业报告，相信这份报告会给黄金市场带来大幅度波动。","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"GS":0.9,"BA":0.9}},"isVote":1,"tweetType":1,"viewCount":4897,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153914555,"gmtCreate":1625004492477,"gmtModify":1703849749154,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087745047715700","authorIdStr":"4087745047715700"},"themes":[],"title":"","htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153914555","repostId":"1102942162","repostType":4,"repost":{"id":"1102942162","kind":"news","pubTimestamp":1624972114,"share":"https://ttm.financial/m/news/1102942162?lang=en_US&edition=fundamental","pubTime":"2021-06-29 21:08","market":"us","language":"zh","title":"In the first half of the year, these 11 biopharmaceutical companies invested by Hillhouse have officially IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1102942162","media":"医药观澜","summary":"2021年高瓴的IPO方向以新一代基因治疗、细胞疗法的创新药为主。就其投资的企业类型来看，创新研发能力强、处于早期阶段的科创企业更受青睐。\n公开资料显示，2021年以来，已经有11家高瓴投资的生物医药","content":"<p>In 2021, Hillhouse's IPO direction will focus on innovative drugs for new generation gene therapy and cell therapy. As far as the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and in the early stage are more favored.</p><p>Public information shows that since 2021, 11 biomedical companies invested by Hillhouse have officially IPO on different stock exchanges. Throughout the 11 IPO projects, they are all technological innovation-driven companies. Among them, there are 7 cutting-edge companies focusing on innovative therapies. Their research fields include cell therapy, innovative ophthalmic drugs, autoimmune diseases and so on. This article will share basic information about these 7 companies for readers' information only.</p><p>1. Keji Pharmaceutical</p><p>Research area: Cell therapy</p><p>Keji Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative cell therapies for the treatment of solid tumors and hematological malignancies. Since its establishment, Keji Pharmaceutical has been developing innovative and differentiated innovative products focusing on CAR-T cell therapy. Public information shows that the company's CAR-T product candidates are evidence-based on new tumor-related antigens and have been carefully designed and optimized to reduce common side effects of existing CAR-T therapies. In June 2021, Keji Pharmaceutical was officially listed on the Hong Kong Stock Exchange.<img src=\"https://static.tigerbbs.com/0718a4dbb06171c8ac471c5b084ded19\" tg-width=\"345\" tg-height=\"129\" referrerpolicy=\"no-referrer\">It is reported that Keji Pharmaceutical has now established a pipeline under development containing 11 product candidates, and 6 are in the clinical development stage. Among them, BCMA-targeted CAR-T therapy CT053 has been granted advanced therapy designation for regenerative medicine (RMAT) and orphan drug designation by the FDA, priority drug designation (PRIME) and orphan drug designation granted by the European Medicines Agency (EMA), and China Breakthrough therapeutic varieties granted by the National Food and Drug Administration (NMPA). In addition, the company's products under development also include CLDN18.2 targeting CAR-T products, autologous CAR-T candidates targeting phosphatidylinositol proteoglycan-3 (GPC3), and so on.</p><p>2. Century Therapeutics</p><p>Research area: Cell therapy</p><p>Century Therapeutics is committed to harnessing the potential of adult stem cells to develop cell therapy products for the treatment of cancer to overcome the limitations of first-generation cell therapies. The company's technology platform relies on induced pluripotent stem cells (iPSCs) with unlimited self-renewal capabilities. The technology uses multiple rounds of cell engineering to create a master cell bank that can expand and differentiate into immune effector cells, thereby providing a large number of allogeneic, homologous therapeutic products. In June 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/ebdab209c719a1865a19e7329210a703\" tg-width=\"570\" tg-height=\"190\" referrerpolicy=\"no-referrer\">According to reports, Century Therapeutics' preclinical R&D projects include a variety of induced pluripotent stem cell-derived CAR-iT and CAR-iNK cell products, which are intended to be developed for the treatment of hematological cancers and solid tumors. Among them, the drug candidate CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy, which is intended to be developed for the treatment of relapsed/refractory B-cell lymphoma. The drug candidate CNTY-103 is a CAR-iNK candidate targeting CD133/EGFR and is intended for the treatment of recurrent glioblastoma (GBM). In addition, the company is also developing drug candidates for the treatment of relapsed/refractory B-cell lymphoma, acute myeloid leukemia (AML) and other diseases.</p><p>3. Lyell Immunopharma</p><p>Research area: Cell therapy</p><p>Lyell Immunopharma aims to develop solid tumor T cell therapies with \"curative\" potential by \"reprogramming\" T cells. In June 2021, the company officially landed on the Nasdaq. Lyell believes that T cell therapy mainly faces two major obstacles in the treatment of solid tumors: First, the depletion of T cells causes it to lose its function of killing tumor cells; Second, the stem cell characteristics of T cells are not durable enough, resulting in limited continuous proliferation and renewal ability of T cell therapy. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms Gen-R and Epi-R to address these barriers to develop innovative therapies.<img src=\"https://static.tigerbbs.com/156517955166f0a82d8bd8c0e03602f3\" tg-width=\"200\" tg-height=\"200\" referrerpolicy=\"no-referrer\">According to reports, LYL797 developed by Lyell is a CAR-T therapy under development targeting ROR1 antigen. This product adds a safety switch based on optimized epidermal growth factor receptor (EGFR) and is intended to be developed for the treatment of ROR1 expression. Non-small cell lung cancer, triple negative breast cancer and other cancers. Another product candidate, LYL845, is an autologous tumor infiltrating lymphocyte (TIL) therapy that is expected to treat a variety of solid tumors. In addition, the company is also working with GlaxoSmithKline (GSK) to develop TCR-T cell therapies targeting NY-ESO-1.</p><p>4. Talaris Therapeutics</p><p>Research area: Cell therapy</p><p>Talaris Therapeutics is committed to developing treatments through disposable cell therapy to permanently solve the problem of organ transplant patients needing long-term immunosuppressive therapy. In May 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/94382e61a569a56d90efdf9e700b4aa4\" tg-width=\"640\" tg-height=\"334\" referrerpolicy=\"no-referrer\">The side effects of long-term immunosuppressive drugs have made Dr. Suzanne Ildstad, the founder of Talaris, determined to develop an innovative treatment to improve the body's immune tolerance. Her research found that there are facilitating cells in the bone marrow. Unlike stem cells, these cells can help stem cells transplanted into the host migrate into the bone marrow, where immune cells and other blood cells are generated. In addition, promoting cells can also enhance the host's immune tolerance and reduce the risk of graft-versus-host disease (GVHD). According to reports, FCR001, a cell therapy under development developed by Talaris, has entered the late-stage clinical trial stage, and it is planned to be developed and treated for patients who have previously received living donor kidney transplantation and patients with severe autoimmune diseases. Previously, the FDA has granted FCR001 orphan drug designation and advanced therapy designation for regenerative medicine (RMAT).</p><p>5. Zhaoke Ophthalmology</p><p>Research area: Ophthalmology innovative drugs</p><p>Zhaoke Ophthalmology is committed to the discovery, development and commercialization of ophthalmic therapies. Through self-development or licensed introduction, Zhaoke Ophthalmology has established a comprehensive ophthalmic drug pipeline comprising 25 drug candidates, including 13 innovative drugs and 12 generic drugs, covering most major ophthalmic indications affecting the anterior and posterior segments of the eye. In April 2021, Zhaoke Ophthalmology was officially listed on the Hong Kong Stock Exchange.</p><p><img src=\"https://static.tigerbbs.com/d46d549a89fd16eba51aeeef02ba7eab\" tg-width=\"640\" tg-height=\"177\" referrerpolicy=\"no-referrer\"></p><p>It is reported that Zhaoke Ophthalmology's preliminary research and development focus focuses on five major ophthalmological indications in China, namely dry eye syndrome (DED), wet senile macular disease (wAMD), diabetic macular edema (DME), myopia and glaucoma. Many ophthalmic diseases develop in multiple stages due to the presence of multiple pathological processes. Therefore, most ophthalmic diseases are heterogeneous diseases. For different ophthalmic indications, Zhaoke Ophthalmology's development strategy is to choose to develop multiple drug candidates with different mechanisms of action, hoping to bring flexible treatment options to patients through monotherapy or combination administration.</p><p>6. Design Therapeutics</p><p>Research Area: Autoimmune Diseases</p><p>Design Therapeutics, which is committed to developing drugs to treat severe degenerative diseases caused by nucleotide repeat amplification, went public on the Nasdaq in March 2021. Nucleotide repeat disease is a kind of genetic disease caused by the repeated amplification of certain short sequences of genes. Depending on their location, repeated sequences may lead to alterations in the regulation of gene expression or to the production of toxic gene products, which are considered to be important factors contributing to degenerative diseases.</p><p><img src=\"https://static.tigerbbs.com/bea91a3c2d92095a7a6f6b3a4d4c8a53\" tg-width=\"640\" tg-height=\"187\" referrerpolicy=\"no-referrer\">According to the official website of Design Therapeutics, the company currently has two major research projects. One of the research projects targeted patients with Friedreich's ataxia (FA). FA is one of the most common types of inherited ataxia. Due to mutations in the FXN gene, the production of frataxin is restricted, which in turn leads to various debilitating symptoms and complications. Another research project targeted the indication of myotonic dystrophy type-1 (DM1). DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease caused by a mutation in the DMPK gene that affects skeletal muscle, heart, brain, and other organs. The main features of the disease include muscle weakness, myotonia (slow muscle relaxation), and early cataracts. Furthermore, affected individuals often experience arrhythmias and changes in neuropsychological functioning.</p><p>7. Instil Bio</p><p>Research area: Cell therapy</p><p>Instil Bio, a global clinical-stage cell therapy company dedicated to the development of tumor-infiltrating lymphocyte therapies for the treatment of cancer, was listed on Nasdaq in March 2021. According to the information from Instil Bio's official website, the company's fastest-developed product under development is ITIL-168, and its clinical trial for the treatment of advanced melanoma is in the phase 1 clinical trial stage. In addition, ITIL-168 is also intended to be developed for the treatment of cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC) and cervical cancer.<img src=\"https://static.tigerbbs.com/10d035fb5dbb022afd385010f2bad15c\" tg-width=\"575\" tg-height=\"269\" referrerpolicy=\"no-referrer\">In addition to the above-mentioned companies, Hillhouse invested in Nanotechnology (research field: nanospheres), Times Angel (research field: oral instruments), Xintong Medical (research field: heart valves), and Beikang Medical (research field: in vitro diagnosis) has also been IPO this year. Due to space limitations, this article will not introduce them one by one.</p><p>For now, Hillhouse's IPO direction in 2021 is dominated by innovative drugs for new generation gene therapy and cell therapy. As far as the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and in the early stage are more favored. For most of these projects, Hillhouse has made multiple rounds of investment and is a long-term backer of these companies.</p><p>It is expected that with the help of capital, these enterprises can introduce innovative products to the market as soon as possible to benefit human health.</p>","source":"lsy1593326364857","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>In the first half of the year, these 11 biopharmaceutical companies invested by Hillhouse have officially IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIn the first half of the year, these 11 biopharmaceutical companies invested by Hillhouse have officially IPO\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">医药观澜</strong><span class=\"h-time small\">2021-06-29 21:08</span>\n</p>\n</h4>\n</header>\n<article>\n<p>In 2021, Hillhouse's IPO direction will focus on innovative drugs for new generation gene therapy and cell therapy. As far as the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and in the early stage are more favored.</p><p>Public information shows that since 2021, 11 biomedical companies invested by Hillhouse have officially IPO on different stock exchanges. Throughout the 11 IPO projects, they are all technological innovation-driven companies. Among them, there are 7 cutting-edge companies focusing on innovative therapies. Their research fields include cell therapy, innovative ophthalmic drugs, autoimmune diseases and so on. This article will share basic information about these 7 companies for readers' information only.</p><p>1. Keji Pharmaceutical</p><p>Research area: Cell therapy</p><p>Keji Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative cell therapies for the treatment of solid tumors and hematological malignancies. Since its establishment, Keji Pharmaceutical has been developing innovative and differentiated innovative products focusing on CAR-T cell therapy. Public information shows that the company's CAR-T product candidates are evidence-based on new tumor-related antigens and have been carefully designed and optimized to reduce common side effects of existing CAR-T therapies. In June 2021, Keji Pharmaceutical was officially listed on the Hong Kong Stock Exchange.<img src=\"https://static.tigerbbs.com/0718a4dbb06171c8ac471c5b084ded19\" tg-width=\"345\" tg-height=\"129\" referrerpolicy=\"no-referrer\">It is reported that Keji Pharmaceutical has now established a pipeline under development containing 11 product candidates, and 6 are in the clinical development stage. Among them, BCMA-targeted CAR-T therapy CT053 has been granted advanced therapy designation for regenerative medicine (RMAT) and orphan drug designation by the FDA, priority drug designation (PRIME) and orphan drug designation granted by the European Medicines Agency (EMA), and China Breakthrough therapeutic varieties granted by the National Food and Drug Administration (NMPA). In addition, the company's products under development also include CLDN18.2 targeting CAR-T products, autologous CAR-T candidates targeting phosphatidylinositol proteoglycan-3 (GPC3), and so on.</p><p>2. Century Therapeutics</p><p>Research area: Cell therapy</p><p>Century Therapeutics is committed to harnessing the potential of adult stem cells to develop cell therapy products for the treatment of cancer to overcome the limitations of first-generation cell therapies. The company's technology platform relies on induced pluripotent stem cells (iPSCs) with unlimited self-renewal capabilities. The technology uses multiple rounds of cell engineering to create a master cell bank that can expand and differentiate into immune effector cells, thereby providing a large number of allogeneic, homologous therapeutic products. In June 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/ebdab209c719a1865a19e7329210a703\" tg-width=\"570\" tg-height=\"190\" referrerpolicy=\"no-referrer\">According to reports, Century Therapeutics' preclinical R&D projects include a variety of induced pluripotent stem cell-derived CAR-iT and CAR-iNK cell products, which are intended to be developed for the treatment of hematological cancers and solid tumors. Among them, the drug candidate CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy, which is intended to be developed for the treatment of relapsed/refractory B-cell lymphoma. The drug candidate CNTY-103 is a CAR-iNK candidate targeting CD133/EGFR and is intended for the treatment of recurrent glioblastoma (GBM). In addition, the company is also developing drug candidates for the treatment of relapsed/refractory B-cell lymphoma, acute myeloid leukemia (AML) and other diseases.</p><p>3. Lyell Immunopharma</p><p>Research area: Cell therapy</p><p>Lyell Immunopharma aims to develop solid tumor T cell therapies with \"curative\" potential by \"reprogramming\" T cells. In June 2021, the company officially landed on the Nasdaq. Lyell believes that T cell therapy mainly faces two major obstacles in the treatment of solid tumors: First, the depletion of T cells causes it to lose its function of killing tumor cells; Second, the stem cell characteristics of T cells are not durable enough, resulting in limited continuous proliferation and renewal ability of T cell therapy. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms Gen-R and Epi-R to address these barriers to develop innovative therapies.<img src=\"https://static.tigerbbs.com/156517955166f0a82d8bd8c0e03602f3\" tg-width=\"200\" tg-height=\"200\" referrerpolicy=\"no-referrer\">According to reports, LYL797 developed by Lyell is a CAR-T therapy under development targeting ROR1 antigen. This product adds a safety switch based on optimized epidermal growth factor receptor (EGFR) and is intended to be developed for the treatment of ROR1 expression. Non-small cell lung cancer, triple negative breast cancer and other cancers. Another product candidate, LYL845, is an autologous tumor infiltrating lymphocyte (TIL) therapy that is expected to treat a variety of solid tumors. In addition, the company is also working with GlaxoSmithKline (GSK) to develop TCR-T cell therapies targeting NY-ESO-1.</p><p>4. Talaris Therapeutics</p><p>Research area: Cell therapy</p><p>Talaris Therapeutics is committed to developing treatments through disposable cell therapy to permanently solve the problem of organ transplant patients needing long-term immunosuppressive therapy. In May 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/94382e61a569a56d90efdf9e700b4aa4\" tg-width=\"640\" tg-height=\"334\" referrerpolicy=\"no-referrer\">The side effects of long-term immunosuppressive drugs have made Dr. Suzanne Ildstad, the founder of Talaris, determined to develop an innovative treatment to improve the body's immune tolerance. Her research found that there are facilitating cells in the bone marrow. Unlike stem cells, these cells can help stem cells transplanted into the host migrate into the bone marrow, where immune cells and other blood cells are generated. In addition, promoting cells can also enhance the host's immune tolerance and reduce the risk of graft-versus-host disease (GVHD). According to reports, FCR001, a cell therapy under development developed by Talaris, has entered the late-stage clinical trial stage, and it is planned to be developed and treated for patients who have previously received living donor kidney transplantation and patients with severe autoimmune diseases. Previously, the FDA has granted FCR001 orphan drug designation and advanced therapy designation for regenerative medicine (RMAT).</p><p>5. Zhaoke Ophthalmology</p><p>Research area: Ophthalmology innovative drugs</p><p>Zhaoke Ophthalmology is committed to the discovery, development and commercialization of ophthalmic therapies. Through self-development or licensed introduction, Zhaoke Ophthalmology has established a comprehensive ophthalmic drug pipeline comprising 25 drug candidates, including 13 innovative drugs and 12 generic drugs, covering most major ophthalmic indications affecting the anterior and posterior segments of the eye. In April 2021, Zhaoke Ophthalmology was officially listed on the Hong Kong Stock Exchange.</p><p><img src=\"https://static.tigerbbs.com/d46d549a89fd16eba51aeeef02ba7eab\" tg-width=\"640\" tg-height=\"177\" referrerpolicy=\"no-referrer\"></p><p>It is reported that Zhaoke Ophthalmology's preliminary research and development focus focuses on five major ophthalmological indications in China, namely dry eye syndrome (DED), wet senile macular disease (wAMD), diabetic macular edema (DME), myopia and glaucoma. Many ophthalmic diseases develop in multiple stages due to the presence of multiple pathological processes. Therefore, most ophthalmic diseases are heterogeneous diseases. For different ophthalmic indications, Zhaoke Ophthalmology's development strategy is to choose to develop multiple drug candidates with different mechanisms of action, hoping to bring flexible treatment options to patients through monotherapy or combination administration.</p><p>6. Design Therapeutics</p><p>Research Area: Autoimmune Diseases</p><p>Design Therapeutics, which is committed to developing drugs to treat severe degenerative diseases caused by nucleotide repeat amplification, went public on the Nasdaq in March 2021. Nucleotide repeat disease is a kind of genetic disease caused by the repeated amplification of certain short sequences of genes. Depending on their location, repeated sequences may lead to alterations in the regulation of gene expression or to the production of toxic gene products, which are considered to be important factors contributing to degenerative diseases.</p><p><img src=\"https://static.tigerbbs.com/bea91a3c2d92095a7a6f6b3a4d4c8a53\" tg-width=\"640\" tg-height=\"187\" referrerpolicy=\"no-referrer\">According to the official website of Design Therapeutics, the company currently has two major research projects. One of the research projects targeted patients with Friedreich's ataxia (FA). FA is one of the most common types of inherited ataxia. Due to mutations in the FXN gene, the production of frataxin is restricted, which in turn leads to various debilitating symptoms and complications. Another research project targeted the indication of myotonic dystrophy type-1 (DM1). DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease caused by a mutation in the DMPK gene that affects skeletal muscle, heart, brain, and other organs. The main features of the disease include muscle weakness, myotonia (slow muscle relaxation), and early cataracts. Furthermore, affected individuals often experience arrhythmias and changes in neuropsychological functioning.</p><p>7. Instil Bio</p><p>Research area: Cell therapy</p><p>Instil Bio, a global clinical-stage cell therapy company dedicated to the development of tumor-infiltrating lymphocyte therapies for the treatment of cancer, was listed on Nasdaq in March 2021. According to the information from Instil Bio's official website, the company's fastest-developed product under development is ITIL-168, and its clinical trial for the treatment of advanced melanoma is in the phase 1 clinical trial stage. In addition, ITIL-168 is also intended to be developed for the treatment of cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC) and cervical cancer.<img src=\"https://static.tigerbbs.com/10d035fb5dbb022afd385010f2bad15c\" tg-width=\"575\" tg-height=\"269\" referrerpolicy=\"no-referrer\">In addition to the above-mentioned companies, Hillhouse invested in Nanotechnology (research field: nanospheres), Times Angel (research field: oral instruments), Xintong Medical (research field: heart valves), and Beikang Medical (research field: in vitro diagnosis) has also been IPO this year. Due to space limitations, this article will not introduce them one by one.</p><p>For now, Hillhouse's IPO direction in 2021 is dominated by innovative drugs for new generation gene therapy and cell therapy. As far as the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and in the early stage are more favored. For most of these projects, Hillhouse has made multiple rounds of investment and is a long-term backer of these companies.</p><p>It is expected that with the help of capital, these enterprises can introduce innovative products to the market as soon as possible to benefit human health.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://wallstreetcn.com/articles/3634131\">医药观澜</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/890dd2dfb205aa8aa1d140672304b3c8","relate_stocks":{"IPSC":"Century Therapeutics, Inc.","02171":"科济药业-B"},"source_url":"https://wallstreetcn.com/articles/3634131","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102942162","content_text":"2021年高瓴的IPO方向以新一代基因治疗、细胞疗法的创新药为主。就其投资的企业类型来看，创新研发能力强、处于早期阶段的科创企业更受青睐。\n公开资料显示，2021年以来，已经有11家高瓴投资的生物医药企业，在不同的证券交易所正式IPO。纵观11个IPO项目，均为科技创新驱动型公司。其中，有7家专注创新疗法的新锐公司，他们的研究领域包括细胞治疗、眼科创新药物、自身免疫疾病等等。本文将分享这7家公司的基本信息，仅供读者参阅。\n1、科济药业\n研究领域：细胞治疗\n科济药业是一家临床阶段的生物医药公司，专注于治疗实体瘤和血液恶性肿瘤的创新细胞疗法。自成立以来，科济药业一直在研发以CAR-T细胞疗法为重点的创新及差异化创新产品。公开资料显示，该公司CAR-T候选产品循证新型肿瘤相关抗原，并经过精心设计和优化，以减少现有CAR-T疗法常见的副作用。2021年6月，科济药业正式在港交所挂牌。据悉，科济药业现已建立一条包含11款候选产品的在研管线，且6款正处于临床开发阶段。其中，BCMA靶向CAR-T疗法CT053曾获FDA授予的再生医学先进疗法认定（RMAT）和孤儿药资格，欧洲药品管理局（EMA）授予的优先药物资格（PRIME）和孤儿药资格，以及中国国家药监局（NMPA）授予的突破性治疗品种。此外，该公司的在研产品还包括CLDN18.2靶向CAR-T产品、靶向磷脂酰肌醇蛋白聚糖-3（GPC3）的自体CAR-T候选产品等等。\n2、Century Therapeutics\n研究领域：细胞治疗\nCentury Therapeutics致力于利用成体干细胞的潜力，开发治疗癌症的细胞疗法产品，以克服第一代细胞疗法的局限性。该公司的技术平台依托于具有无限自我更新能力的诱导多能干细胞（iPSC）。该技术通过多轮细胞工程来创建主细胞库，这些细胞可扩展和分化成免疫效应细胞，从而提供大量同种异体、同源的治疗产品。2021年6月，该公司在纳斯达克上市。据介绍，Century Therapeutics公司的临床前研发项目包括多种诱导多能干细胞衍生的CAR-iT和CAR-iNK细胞产品，拟开发用于治疗血液癌症和实体瘤。其中，候选药物CNTY-101是一种同种异体、iPSC衍生的CAR-iNK细胞疗法，拟开发用于治疗复发性/难治性B细胞淋巴瘤。候选药物CNTY-103为靶向CD133/EGFR的CAR-iNK候选物，拟用于治疗复发性胶质母细胞瘤（GBM）。此外，该公司还在开发用于治疗复发性/难治性B细胞淋巴瘤、急性髓系白血病（AML）等疾病的候选药物。\n3、Lyell Immunopharma\n研究领域：细胞治疗\nLyell Immunopharma旨在通过对T细胞进行“重编程”（reprogramming），开发具有“治愈”潜力的实体瘤T细胞疗法。2021年6月，该公司正式登陆纳斯达克。Lyell公司认为，T细胞疗法在治疗实体瘤治疗方面主要面临两大障碍：一是，T细胞耗竭导致其失去杀伤肿瘤细胞的功能；二是，T细胞的干细胞特征不够持久，导致T细胞疗法的持续增殖和更新能力有限。Lyell公司正在应用其专有的离体遗传和表观遗传重编程技术平台Gen-R和Epi-R来解决这些障碍，以开发创新疗法。据介绍，Lyell公司开发的LYL797是一款靶向ROR1抗原的在研CAR-T疗法，该产品添加了一个基于优化的表皮生长因子受体（EGFR）的安全开关，拟开发用于治疗表达ROR1的非小细胞肺癌、三阴性乳腺癌等癌症。另一款候选产品LYL845是一种自体肿瘤浸润淋巴细胞（TIL）疗法，有望治疗多种实体瘤。此外，该公司还在与葛兰素史克（GSK）合作开发靶向NY-ESO-1的TCR-T细胞疗法。\n4、Talaris Therapeutics\n研究领域：细胞治疗\nTalaris Therapeutics致力于开发通过一次性细胞疗法的治疗，永久性解决器官移植患者需要接受长期免疫抑制疗法的难题。2021年5月，该公司在纳斯达克上市。长期服用免疫抑制药物的副作用，让Talaris公司的创始人Suzanne Ildstad博士决心开发一种提高机体免疫耐受力的创新疗法。她的研究发现骨髓中存在一种促进细胞（facilitating cell），这些细胞与干细胞不同，它们能够帮助移植到宿主体内的干细胞迁移到骨髓中，在那里生成免疫细胞和其它血细胞。此外，促进细胞还能够增强宿主的免疫耐受能力，降低移植物抗宿主病（GVHD）产生的风险。据介绍，Talaris公司开发的在研细胞疗法FCR001已进入后期临床试验阶段，拟开发治疗以前接受活体供体肾脏移植的患者、重度自身免疫性疾病患者等。此前，FDA已授予FCR001孤儿药资格和再生医学先进疗法认定（RMAT）。\n5、兆科眼科\n研究领域：眼科创新药\n兆科眼科致力于发现、开发及商业化眼科疗法。通过自主开发或许可引进，兆科眼科已建立起一条包含25种候选药物（包含13种创新药和12种仿制药）的全面眼科药物管线，涵盖影响眼前节及眼后节的多数主要眼科适应症。2021年4月，兆科眼科正式在港交所上市。\n\n据悉，兆科眼科初步研发重心聚焦中国五大眼科适应症上，即干眼症(DED)、湿性老年黄斑部病变(wAMD)、糖尿病黄斑水肿(DME)、近视眼以及青光眼。由于存在多种病理过程，许多眼科疾病的发展分多个阶段。因此，大部分眼科疾病属于异质性疾病。对于不同的眼科适应症，兆科眼科的开发策略是选择开发具有不同作用机制的多种候选药物，希望通过单一疗法或联合给药，给患者带来灵活的治疗选择。\n6、Design Therapeutics\n研究领域：自身免疫疾病\nDesign Therapeutics致力于开发治疗由核苷酸重复序列扩增引起的严重退行性疾病的药物，该公司于2021年3月在纳斯达克上市。核苷酸重复序列疾病是由基因的某些短序列重复扩增而引起的一类遗传性疾病。根据其所处位置，重复序列可能会导致基因表达调控的改变或产生有毒的基因产物，它们被认为是造成退行性疾病的重要因素。\n根据Design Therapeutics官网，该公司目前有两个主要研究项目。其中一个研究项目针对的适应症为Friedreich共济失调（Friedreich’s ataxia，FA）患者。FA是一种最常见的遗传性共济失调类型，由于FXN基因的突变，限制了共济蛋白（frataxin）的产生，进而导致各种衰弱的症状和并发症。另一个研究项目针对的适应症为强直性肌营养不良1型(myotonic dystrophy type-1，DM1)。DM1是一种单基因、常染色体显性遗传、进行性神经肌肉疾病，由DMPK基因突变引起，影响骨骼肌、心脏、大脑和其他器官。该病的主要特征包括肌肉无力、肌强直（肌肉松弛缓慢）和早期白内障。此外，受影响的个体经常会出现心律失常和神经心理功能的变化。\n7、Instil Bio\n研究领域：细胞治疗\nInstil Bio是一家全球性的临床阶段细胞疗法公司，致力于开发治疗癌症的肿瘤浸润淋巴细胞疗法，该公司于2021年3月在纳斯达克上市。Instil Bio官网信息显示，该公司研究进度最快的在研产品为ITIL-168，其治疗晚期黑色素瘤的临床试验已处于1期临床试验阶段。此外，ITIL-168还拟被开发用于治疗皮肤鳞状细胞癌（CSCC）、非小细胞肺癌（NSCLC）和宫颈癌等适应症。除了上述企业，高瓴投资的纳微科技（研究领域：纳米微球）、时代天使（研究领域：口腔器械）、心通医疗（研究领域：心脏瓣膜）、贝康医疗（研究领域：体外诊断）也已在今年IPO。限于篇幅，本文不再一一介绍。\n就目前来看，2021年高瓴的IPO方向以新一代基因治疗、细胞疗法的创新药为主。就其投资的企业类型来看，创新研发能力强、处于早期阶段的科创企业更受青睐。对于其中大部分项目，高瓴都进行了多轮投资，是这些公司的长期支持者。\n期待这些企业在资本的助力下，可以早日将创新产品推出市场，造福人类健康。","news_type":1,"symbols_score_info":{"02171":0.9,"IPSC":0.9}},"isVote":1,"tweetType":1,"viewCount":4918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153914608,"gmtCreate":1625004466104,"gmtModify":1703849748662,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087745047715700","authorIdStr":"4087745047715700"},"themes":[],"title":"","htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153914608","repostId":"1146206014","repostType":4,"repost":{"id":"1146206014","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624973528,"share":"https://ttm.financial/m/news/1146206014?lang=en_US&edition=fundamental","pubTime":"2021-06-29 21:32","market":"us","language":"zh","title":"Opening: Nasdaq and S&P hit another record high, blockchain sector rose broadly","url":"https://stock-news.laohu8.com/highlight/detail?id=1146206014","media":"老虎资讯综合","summary":"6月29日，美国股市三大指数小幅高开，纳指与标普500指数再创历史新高。截至发稿，道指上涨0.34%，纳指上涨0.06%，标普500指数上涨0.14%。\n区块链板块普涨，Riot Blockchain","content":"<p>On June 29th, the three major indexes of the U.S. stock market opened slightly higher, and the Nasdaq and S&P 500 reached another record high. At press time, the Dow is up 0.34%, the Nasdaq is up 0.06% and the S&P 500 is up 0.14%.</p><p><img src=\"https://static.tigerbbs.com/2e4b11b4f251daeec3a6e30b91c722ad\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">The Blockchain sector rose generally, Riot Blockchain,<a href=\"https://laohu8.com/S/NCTY\">9th City</a>Up more than 5%,<a href=\"https://laohu8.com/S/CAN\">Canaan Technology</a>It rose by more than 3%.</p><p>Most popular Chinese stocks fell,<a href=\"https://laohu8.com/S/NTES\">Netease</a>Youdao fell more than 3%,<a href=\"https://laohu8.com/S/BILI\">Bilibili</a>、<a href=\"https://laohu8.com/S/PDD\">Pinduoduo</a>、<a href=\"https://laohu8.com/S/BIDU\">Baidu</a>、<a href=\"https://laohu8.com/S/BABA\">Alibaba</a>It fell by more than 1%.</p><p><a href=\"https://laohu8.com/S/BA\">boeing</a>Up nearly 2%, United is reported to have ordered several<a href=\"https://laohu8.com/S/BA\">boeing</a>Planes.</p><p><a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>up 3.8% after the company announced it would double its Dividend and increase share buybacks.</p><p>Cloud enterprise marketing Software Marin Software rose 22.67%. The company has gained nearly 340% in the past three days. On the news, the company announced that its flagship platform MarinOne has added the ability to manage Instacart ads.</p><p><a href=\"https://laohu8.com/S/HOLI\">Hollysys Automation</a>up 5.56%. The company announced today that a group of buyers comprising CPE Funds Management Limited, Pak-Ching Shao and Ace Lead Profits Limited has sought consent from the company's shareholders for its proposed acquisition of Hollysys Automation.</p><p><a href=\"https://laohu8.com/S/00013\">Hutchison Medicine</a>It fell 1.55%. Today, its Hong Kong stocks closed up about 25% in dark market trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opening: Nasdaq and S&P hit another record high, blockchain sector rose broadly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpening: Nasdaq and S&P hit another record high, blockchain sector rose broadly\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-29 21:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On June 29th, the three major indexes of the U.S. stock market opened slightly higher, and the Nasdaq and S&P 500 reached another record high. At press time, the Dow is up 0.34%, the Nasdaq is up 0.06% and the S&P 500 is up 0.14%.</p><p><img src=\"https://static.tigerbbs.com/2e4b11b4f251daeec3a6e30b91c722ad\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">The Blockchain sector rose generally, Riot Blockchain,<a href=\"https://laohu8.com/S/NCTY\">9th City</a>Up more than 5%,<a href=\"https://laohu8.com/S/CAN\">Canaan Technology</a>It rose by more than 3%.</p><p>Most popular Chinese stocks fell,<a href=\"https://laohu8.com/S/NTES\">Netease</a>Youdao fell more than 3%,<a href=\"https://laohu8.com/S/BILI\">Bilibili</a>、<a href=\"https://laohu8.com/S/PDD\">Pinduoduo</a>、<a href=\"https://laohu8.com/S/BIDU\">Baidu</a>、<a href=\"https://laohu8.com/S/BABA\">Alibaba</a>It fell by more than 1%.</p><p><a href=\"https://laohu8.com/S/BA\">boeing</a>Up nearly 2%, United is reported to have ordered several<a href=\"https://laohu8.com/S/BA\">boeing</a>Planes.</p><p><a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>up 3.8% after the company announced it would double its Dividend and increase share buybacks.</p><p>Cloud enterprise marketing Software Marin Software rose 22.67%. The company has gained nearly 340% in the past three days. On the news, the company announced that its flagship platform MarinOne has added the ability to manage Instacart ads.</p><p><a href=\"https://laohu8.com/S/HOLI\">Hollysys Automation</a>up 5.56%. The company announced today that a group of buyers comprising CPE Funds Management Limited, Pak-Ching Shao and Ace Lead Profits Limited has sought consent from the company's shareholders for its proposed acquisition of Hollysys Automation.</p><p><a href=\"https://laohu8.com/S/00013\">Hutchison Medicine</a>It fell 1.55%. Today, its Hong Kong stocks closed up about 25% in dark market trading.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","relate_stocks":{".IXIC":"NASDAQ Composite","QID":"两倍做空纳斯达克指数ETF-ProShares","PSQ":"做空纳斯达克100指数ETF-ProShares","QQQ":"纳指100ETF","TQQQ":"纳指三倍做多ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares","SQQQ":"纳指三倍做空ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯","03086":"华夏纳指"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146206014","content_text":"6月29日，美国股市三大指数小幅高开，纳指与标普500指数再创历史新高。截至发稿，道指上涨0.34%，纳指上涨0.06%，标普500指数上涨0.14%。\n区块链板块普涨，Riot Blockchain、第九城市涨超5%，嘉楠科技涨超3%。\n多数热门中概股走低，网易有道跌逾3%，哔哩哔哩、拼多多、百度、阿里巴巴跌超1%。\n波音涨近2%，据悉美联航订购了数辆波音飞机。\n摩根士丹利涨3.8%，此前公司宣布将股息加倍，并增加股票回购。\n云企业营销软件Marin Software涨22.67%。该公司近三日累计涨幅近340%。消息面上，公司宣布其旗舰平台MarinOne增加了管理Instacart广告的能力。\n和利时自动化涨5.56%。该公司今日宣布，由CPE Funds Management Limited、邵柏庆及Ace Lead Profits Limited组成的买方团就其对和利时自动化的拟议收购，向公司股东征求同意。\n和黄医药跌1.55%，今日其港股暗盘交易收涨约25%。","news_type":1,"symbols_score_info":{"TQQQ":0.9,"QLD":0.9,".IXIC":0.9,"ESmain":0.9,"QID":0.9,"03086":0.9,"MNQmain":0.9,"SQQQ":0.9,".DJI":0.9,"NQmain":0.9,"PSQ":0.9,".SPX":0.9,"QQQ":0.9}},"isVote":1,"tweetType":1,"viewCount":5818,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153914035,"gmtCreate":1625004421927,"gmtModify":1703849748166,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087745047715700","authorIdStr":"4087745047715700"},"themes":[],"title":"","htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153914035","repostId":"2147904866","repostType":4,"isVote":1,"tweetType":1,"viewCount":4063,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153915947,"gmtCreate":1625004310889,"gmtModify":1703849746528,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087745047715700","authorIdStr":"4087745047715700"},"themes":[],"title":"","htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153915947","repostId":"2147468863","repostType":4,"isVote":1,"tweetType":1,"viewCount":4730,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153913013,"gmtCreate":1625003795032,"gmtModify":1703849739461,"author":{"id":"4087745047715700","authorId":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087745047715700","authorIdStr":"4087745047715700"},"themes":[],"title":"","htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153913013","repostId":"1106873810","repostType":4,"repost":{"id":"1106873810","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624989419,"share":"https://ttm.financial/m/news/1106873810?lang=en_US&edition=fundamental","pubTime":"2021-06-30 01:56","market":"us","language":"zh","title":"Ding Dong Maicai officially landed on NYSE and opened 21% on the first day","url":"https://stock-news.laohu8.com/highlight/detail?id=1106873810","media":"老虎资讯综合","summary":"北京时间6月30日，叮咚买菜正式登陆纽交所，首日开涨21%，此前给出的IPO发行价为每份ADS 23.50美元。\n\n上市前夕发行规模缩减7成\n叮咚买菜在上市前夜紧急更新了IPO招股书，据最新招股书显示","content":"<p>On June 30th, Beijing time, Ding Dong Maicai officially landed on the New York Stock Exchange, rising by 21% on the first day. The previous IPO issue price was $23.50 per ADS.</p><p><img src=\"https://static.tigerbbs.com/8019015b6d73a8f99bab4121482e7be7\" tg-width=\"827\" tg-height=\"595\" referrerpolicy=\"no-referrer\"></p><p><b>On the eve of listing, the issuance scale was reduced by 70%</b></p><p>Dingdong Maicai urgently updated its IPO prospectus on the eve of its listing. According to the latest prospectus, Dingdong Maicai has reduced its goal of listing and financing in the United States to about a quarter of the original, that is, it seeks to raise up to 94.4 million USD, which is 74% lower than the originally planned financing of 357 million USD. The number of depositary shares (ADS) issued has also been cut from 14 million shares to 3.7 million shares, with a price range of 23.50 USD to 25.50 USD.</p><p>A week ago, Dingdong Maicai's first updated prospectus showed that it would publicly issue 14 million American depositary shares. At that time, it could raise nearly $360 million according to the upper limit of the offering price range. In contrast, the last announced fundraising scale was reduced to a quarter of the previous quota, that is, the overall reduction was over 70%.</p><p><b>About Dingdong Grocery Buying</b></p><p>Dingdong Maicai is headquartered in Shanghai and operates its own grocery app. Consumers can buy fresh food on demand through the \"front warehouse\" network. The so-called front warehouse is a warehouse located close to residential areas according to the established strategy, so as to ensure that Ding Dong's groceries can be delivered to your door within 30 minutes as promised. Their services have now covered a range of major cities such as Shanghai, Beijing, Shenzhen and Hangzhou.</p><p>Ding Dong Maicai was born in 2017. Liang Changlin, the founder and CEO, had many successful entrepreneurial experiences before, so it quickly attracted the support of a series of venture capital, including Sequoia China and Qiming Venture Capital. In addition, such as Tiger Global, Gaorong Capital and Dachen Caizhi were also among the shareholders of the company. With the support of strong capital, it took Ding Dong only seven months to buy groceries, and the number of its front warehouses tripled to 345.</p><p>According to reports, in February 2020, against the background of the outbreak of COVID-19, Dingdong Maicai had to execute about 300,000 orders every day in Shanghai, and the company's total revenue that year also reached about 1.7 billion US dollars. As of January 2021, Dingdong Maicai's business has covered nearly 30 cities across the country, with about 1,000 front-end warehouses and a monthly user base of about 6.9 million.</p><p>In this field, the main competitors of Dingdong Maicai include Alibaba's Box Horse, Meituan Maicai, Daily Youxian and JD.COM Daojia.</p><p><b>Financial Performance</b></p><p>The recent financial performance of Dingdong Maicai can be roughly summarized as follows: the revenue has grown rapidly, but it is suspected to have peaked; Operating losses and net losses continued to expand, and the net loss ratio fluctuated; The burning of money is considerable, and the free cash flow is still negative.</p><p>Specifically, in 2020, Dingdong's grocery revenue reached 11.336 billion yuan, a 192.16% increase from 3.88 billion yuan in 2019. In the first quarter of 2021, the company's revenue was 3.802 billion yuan, a year-on-year increase of 46.01%.</p><p>In 2020, Dingdong Maicai's operating loss was RMB3.162 billion, representing an increase of 78.42% from RMB1.741 billion in 2019. In the first quarter of 2021, the company's operating loss was RMB1.334 billion, representing a year-on-year increase of 352.20%.</p><p>In 2020, Dingdong Maicai's net loss was RMB3.175 billion, an increase of 69.51% from RMB1.873 billion in 2019. In the first quarter of 2021, the company's net loss was RMB1.385 billion, an increase of 465.31% year-on-year.</p><p>In 2020, the net loss rate of Dingdong Maicai was 28.0%, which was significantly lower than 48.3% in 2019. However, in the first quarter of 2021, the net loss rate soared from 9.4% in the same period of the previous year to 36.4%.</p><p>As of March 31, 2021, Dingdong Maicai had total liabilities of US$898 million and cash and equivalents held of US$973 million. For the twelve months ended March 31, 2021, the Company's free cash flow was-$155 million.</p><p><b>Analysis Comments</b></p><p>According to the established strategy, the profit of Dingdong Maicai mainly comes from the sales of fresh food and other commodities completed through app. However, at present, they are far from achieving profitability, and they can't see a clear roadmap, so that the front warehouse model itself adopted by Dingdong Maicai and other competitors is questioned by market observers from time to time.</p><p>So far, Ding Dong has failed to achieve profitability, and from the financial data, their losses even have the momentum of expanding, and there is no clear profit prospect at all.</p><p>Although the market where Ding Dong groceries is located has a bright future in theory, the fierce competition and low profit margins here are well known. For example, it is reported that the order execution cost of Ding Dong's grocery purchase, including distribution fee, packaging fee, logistics cost, etc., will be twice the net revenue of the order itself in 2020.</p><p>This means that no matter how the number of orders of the company grows, it is not enough for Ding Dong to turn losses into profits in a short time, because the fact is that the more orders, the greater the loss. In fact, the front warehouse mode itself is a \"gold-swallowing beast\", and it is already a severe challenge for the company to control the burning speed of this mode.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ding Dong Maicai officially landed on NYSE and opened 21% on the first day</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDing Dong Maicai officially landed on NYSE and opened 21% on the first day\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-30 01:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On June 30th, Beijing time, Ding Dong Maicai officially landed on the New York Stock Exchange, rising by 21% on the first day. The previous IPO issue price was $23.50 per ADS.</p><p><img src=\"https://static.tigerbbs.com/8019015b6d73a8f99bab4121482e7be7\" tg-width=\"827\" tg-height=\"595\" referrerpolicy=\"no-referrer\"></p><p><b>On the eve of listing, the issuance scale was reduced by 70%</b></p><p>Dingdong Maicai urgently updated its IPO prospectus on the eve of its listing. According to the latest prospectus, Dingdong Maicai has reduced its goal of listing and financing in the United States to about a quarter of the original, that is, it seeks to raise up to 94.4 million USD, which is 74% lower than the originally planned financing of 357 million USD. The number of depositary shares (ADS) issued has also been cut from 14 million shares to 3.7 million shares, with a price range of 23.50 USD to 25.50 USD.</p><p>A week ago, Dingdong Maicai's first updated prospectus showed that it would publicly issue 14 million American depositary shares. At that time, it could raise nearly $360 million according to the upper limit of the offering price range. In contrast, the last announced fundraising scale was reduced to a quarter of the previous quota, that is, the overall reduction was over 70%.</p><p><b>About Dingdong Grocery Buying</b></p><p>Dingdong Maicai is headquartered in Shanghai and operates its own grocery app. Consumers can buy fresh food on demand through the \"front warehouse\" network. The so-called front warehouse is a warehouse located close to residential areas according to the established strategy, so as to ensure that Ding Dong's groceries can be delivered to your door within 30 minutes as promised. Their services have now covered a range of major cities such as Shanghai, Beijing, Shenzhen and Hangzhou.</p><p>Ding Dong Maicai was born in 2017. Liang Changlin, the founder and CEO, had many successful entrepreneurial experiences before, so it quickly attracted the support of a series of venture capital, including Sequoia China and Qiming Venture Capital. In addition, such as Tiger Global, Gaorong Capital and Dachen Caizhi were also among the shareholders of the company. With the support of strong capital, it took Ding Dong only seven months to buy groceries, and the number of its front warehouses tripled to 345.</p><p>According to reports, in February 2020, against the background of the outbreak of COVID-19, Dingdong Maicai had to execute about 300,000 orders every day in Shanghai, and the company's total revenue that year also reached about 1.7 billion US dollars. As of January 2021, Dingdong Maicai's business has covered nearly 30 cities across the country, with about 1,000 front-end warehouses and a monthly user base of about 6.9 million.</p><p>In this field, the main competitors of Dingdong Maicai include Alibaba's Box Horse, Meituan Maicai, Daily Youxian and JD.COM Daojia.</p><p><b>Financial Performance</b></p><p>The recent financial performance of Dingdong Maicai can be roughly summarized as follows: the revenue has grown rapidly, but it is suspected to have peaked; Operating losses and net losses continued to expand, and the net loss ratio fluctuated; The burning of money is considerable, and the free cash flow is still negative.</p><p>Specifically, in 2020, Dingdong's grocery revenue reached 11.336 billion yuan, a 192.16% increase from 3.88 billion yuan in 2019. In the first quarter of 2021, the company's revenue was 3.802 billion yuan, a year-on-year increase of 46.01%.</p><p>In 2020, Dingdong Maicai's operating loss was RMB3.162 billion, representing an increase of 78.42% from RMB1.741 billion in 2019. In the first quarter of 2021, the company's operating loss was RMB1.334 billion, representing a year-on-year increase of 352.20%.</p><p>In 2020, Dingdong Maicai's net loss was RMB3.175 billion, an increase of 69.51% from RMB1.873 billion in 2019. In the first quarter of 2021, the company's net loss was RMB1.385 billion, an increase of 465.31% year-on-year.</p><p>In 2020, the net loss rate of Dingdong Maicai was 28.0%, which was significantly lower than 48.3% in 2019. However, in the first quarter of 2021, the net loss rate soared from 9.4% in the same period of the previous year to 36.4%.</p><p>As of March 31, 2021, Dingdong Maicai had total liabilities of US$898 million and cash and equivalents held of US$973 million. For the twelve months ended March 31, 2021, the Company's free cash flow was-$155 million.</p><p><b>Analysis Comments</b></p><p>According to the established strategy, the profit of Dingdong Maicai mainly comes from the sales of fresh food and other commodities completed through app. However, at present, they are far from achieving profitability, and they can't see a clear roadmap, so that the front warehouse model itself adopted by Dingdong Maicai and other competitors is questioned by market observers from time to time.</p><p>So far, Ding Dong has failed to achieve profitability, and from the financial data, their losses even have the momentum of expanding, and there is no clear profit prospect at all.</p><p>Although the market where Ding Dong groceries is located has a bright future in theory, the fierce competition and low profit margins here are well known. For example, it is reported that the order execution cost of Ding Dong's grocery purchase, including distribution fee, packaging fee, logistics cost, etc., will be twice the net revenue of the order itself in 2020.</p><p>This means that no matter how the number of orders of the company grows, it is not enough for Ding Dong to turn losses into profits in a short time, because the fact is that the more orders, the greater the loss. In fact, the front warehouse mode itself is a \"gold-swallowing beast\", and it is already a severe challenge for the company to control the burning speed of this mode.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8bdbf77f2a44d0a051afa32e60a46fbf","relate_stocks":{"DDL":"叮咚买菜"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106873810","content_text":"北京时间6月30日，叮咚买菜正式登陆纽交所，首日开涨21%，此前给出的IPO发行价为每份ADS 23.50美元。\n\n上市前夕发行规模缩减7成\n叮咚买菜在上市前夜紧急更新了IPO招股书，据最新招股书显示，叮咚买菜将在美国上市融资的目标降低到了原来的四分之一左右，即寻求至多融资9440万美元，比原计划融资的3.57亿美元下降了74%，存托股票(ADS) 发行数量也从1400万股砍到了370万股，价格区间为23.50美元至25.50美元。\n一周前，叮咚买菜首次更新的招股书显示其将公开发行1400万股美国存托股票，彼时按照发行价区间上限计算可筹资达到近3.6亿美元。对比之下，最近一次宣布的募资规模缩减至此前额度的四分之一，即总体缩减幅度超70%。\n关于叮咚买菜\n叮咚买菜总部位于上海，运营着自己的买菜app，消费者可以通过“前置仓”网络购买按需生鲜食品。所谓前置仓，是按照既定策略配置在接近居民区的仓库，确保叮咚买菜能够按照承诺，在三十分钟内送货上门。他们的服务目前已经覆盖了上海、北京、深圳和杭州等一系列主要城市。\n叮咚买菜诞生于2017年，创始人兼首席执行官梁昌霖之前就有多次成功创业的经历，因此很快就吸引了一系列风投资本的支持，包括红杉中国、启明创投等，此外诸如老虎环球、高榕资本、达晨财智等也都在公司股东之列。在雄厚的资本支持下，叮咚买菜只用了七个月时间，就让其前置仓数量增长了三倍，达到了345处。\n据报道，2020年2月，在新冠病毒疫情大爆发的背景下，叮咚买菜在上海每天都要执行大约30万笔订单，公司当年的总营收也达到了大约17亿美元。截至2021年1月，叮咚买菜的业务已经覆盖全国近三十个城市，拥有大约一千家前置仓，每月用户群达到大约690万。\n在这个领域当中，叮咚买菜主要的竞争对手包括阿里巴巴旗下盒马、美团买菜、每日优鲜和京东到家等。\n财务表现\n叮咚买菜近期的财务表现可以大致概括如下：营收高速增长，但疑似已经见顶；运营亏损和净亏损持续扩大，净亏损率起伏不定；烧钱可观，自由现金流依然为负数。\n具体而言，2020年当中，叮咚买菜营收达到113.36亿元人民币，较之2019年的38.80亿元猛增192.16%，2021年第一季度，公司营收38.02亿元，同比增长46.01%。\n2020年当中，叮咚买菜运营亏损31.62亿元人民币，较之2019年的17.41亿元扩大78.42%，2021年第一季度，公司运营亏损13.34亿元，同比扩大352.20%。\n2020年当中，叮咚买菜净亏损31.75亿元人民币，较之2019年的18.73亿元扩大69.51%，2021年第一季度，公司净亏损13.85亿元，同比扩大465.31%。\n2020年当中，叮咚买菜净亏损率28.0%，较之2019年的48.3%大幅降低，但是2021年第一季度，净亏损率又从前一年同期的9.4%猛增到了36.4%。\n截至2021年3月31日，叮咚买菜总负债8.98亿美元，持有现金及等价物9.73亿美元。截至2021年3月31日的十二个月当中，公司自由现金流-1.55亿美元。\n分析评论\n按照既定策略，叮咚买菜的利润主要是来自于通过app完成的生鲜食品和其他各种商品的销售，只是目前，他们还远没有到实现盈利的地步，也看不到清晰的路线图，以至于叮咚买菜和其他竞争对手所采用的前置仓模式本身，都不时受到市场观察家们的质疑。\n迄今为止，叮咚买菜都未能实现盈利，而且从财务数据看，他们的亏损甚至还有扩大的势头，根本看不到明确的盈利前景。\n叮咚买菜所在的市场虽然理论上说来前途远大，但是这里的竞争之激烈和利润率之低也是人尽皆知。比如据报道，叮咚买菜的订单执行成本包括配送费、包装费、物流成本等在内，在2020年内要两倍于订单本身的净营收。\n这也就意味着，不管公司的订单数量如何增长，都不足以让叮咚买菜在短期之内扭亏为盈，因为事实就是，订单越多，亏损越大。事实上，前置仓模式本身就是一头“吞金兽”，要控制这种模式的烧钱速度，已经是摆在公司面前的严峻挑战。","news_type":1,"symbols_score_info":{"DDL":0.9}},"isVote":1,"tweetType":1,"viewCount":4816,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}